<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Macrolide antibiotics (including azithromycin) for cystic fibrosis - Southern, KW - 2024 | Cochrane Library</title> <meta content="Macrolide antibiotics (including azithromycin) for cystic fibrosis - Southern, KW - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002203.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Macrolide antibiotics (including azithromycin) for cystic fibrosis - Southern, KW - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002203.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002203.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Macrolide antibiotics (including azithromycin) for cystic fibrosis" name="citation_title"/> <meta content="Kevin W Southern" name="citation_author"/> <meta content="kwsouth@liverpool.ac.uk" name="citation_author_email"/> <meta content="Arturo Solis-Moya" name="citation_author"/> <meta content="Hospital Nacional de Niños" name="citation_author_institution"/> <meta content="Dominiki Kurz" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Sherie Smith" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD002203.pub5" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/02/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002203.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002203.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002203.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [adverse effects]; *Azithromycin [adverse effects]; *Cystic Fibrosis [complications, drug therapy, genetics]; Drug Resistance, Bacterial; Macrolides [adverse effects]; Pseudomonas aeruginosa; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002203.pub5&amp;doi=10.1002/14651858.CD002203.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002203\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002203\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002203.pub5",title:"Macrolide antibiotics (including azithromycin) for cystic fibrosis",firstPublishedDate:"Feb 27, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002203.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002203.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002203.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002203.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002203.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002203.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Абстракт&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002203.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002203.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002203.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002203.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1232 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002203.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0154"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-sec-0140"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/appendices#CD002203-sec-0159"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/supinfo/CD002203-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/supinfo/CD002203-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Macrolide antibiotics (including azithromycin) for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#CD002203-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Kevin W Southern</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#CD002203-cr-0005">Arturo Solis-Moya</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#CD002203-cr-0006">Dominiki Kurz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information#CD002203-cr-0007">Sherie Smith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information/en#CD002203-sec-0168">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 February 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002203.pub5">https://doi.org/10.1002/14651858.CD002203.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002203-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002203-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002203-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002203-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002203-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002203-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002203-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002203-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002203-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002203-abs-0001" lang="en"> <section id="CD002203-sec-0001"> <h3 class="title" id="CD002203-sec-0001">Background</h3> <p>Cystic fibrosis (CF) is a life‐limiting genetic condition, affecting over 90,000 people worldwide. CF affects several organs in the body, but airway damage has the most profound impact on quality of life (QoL) and survival. Causes of lower airway infection in people with CF are, most notably, <i>Staphylococcus aureus</i> in the early course of the disease and <i>Pseudomonas aeruginosa</i> at a later stage. </p> <p>Macrolide antibiotics, e.g. azithromycin and clarithromycin, are usually taken orally, have a broad spectrum of action against gram‐positive (e.g. <i>S aureus</i> ) and some gram‐negative bacteria (e.g. <i>Haemophilus influenzae</i>), and may have a modifying role in diseases involving airway infection and inflammation such as CF. They are well‐tolerated and relatively inexpensive, but widespread use has resulted in the emergence of resistant bacteria. </p> <p>This is an updated review.</p> </section> <section id="CD002203-sec-0002"> <h3 class="title" id="CD002203-sec-0002">Objectives</h3> <p>To assess the potential effects of macrolide antibiotics on clinical status in terms of benefit and harm in people with CF. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy. </p> </section> <section id="CD002203-sec-0003"> <h3 class="title" id="CD002203-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals, and abstract books of conference proceedings. We last searched the Group's Cystic Fibrosis Trials Register on 2 November 2022. </p> <p>We last searched the trial registries WHO ICTRP and clinicaltrials.gov on 9 November 2022. </p> <p>We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow‐up data, where possible. </p> </section> <section id="CD002203-sec-0004"> <h3 class="title" id="CD002203-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of macrolide antibiotics in adults and children with CF. We compared them to: placebo; another class of antibiotic; another macrolide antibiotic; or the same macrolide antibiotic at a different dose or type of administration. </p> </section> <section id="CD002203-sec-0005"> <h3 class="title" id="CD002203-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed risk of bias. We assessed the certainty of evidence using GRADE. </p> </section> <section id="CD002203-sec-0006"> <h3 class="title" id="CD002203-sec-0006">Main results</h3> <p>We included 14 studies (1467 participants) lasting 28 days to 36 months. All the studies assessed azithromycin: 11 compared oral azithromycin to placebo (1167 participants); one compared a high dose to a low dose (47 participants); one compared nebulised to oral azithromycin (45 participants); and one looked at weekly versus daily dose (208 participants). </p> <p><b>Oral azithromycin versus placebo</b> </p> <p>There is a slight improvement in forced expiratory volume (FEV<sub>1</sub> % predicted) in one second in the azithromycin group at up to six months compared to placebo (mean difference (MD) 3.97, 95% confidence interval (CI) 1.74 to 6.19; high‐certainty evidence), although there is probably no difference at three months, (MD 2.70%, 95% CI ‐0.12 to 5.52), or 12 months (MD ‐0.13, 95% CI ‐4.96 to 4.70). Participants in the azithromycin group are probably at a decreased risk of pulmonary exacerbation with a longer time to exacerbation (hazard ratio (HR) 0.61, 95% CI 0.50 to 0.75; moderate‐certainty evidence). Mild side effects were common, but there was no difference between groups (moderate‐certainty evidence). There is no difference in hospital admissions at six months (odds ratio (OR) 0.61, 95% CI 0.36 to 1.04; high‐certainty evidence), or in new acquisition of <i>P aeruginosa</i> at 12 months (HR 1.00, 95% CI 0.64 to 1.55; moderate‐certainty evidence). </p> <p><b>High‐dose versus low‐dose azithromycin</b> </p> <p>We are uncertain whether there is any difference in FEV<sub>1</sub> % predicted at six months between the two groups (no data available) or in the rate of exacerbations per child per month (MD ‐0.05 (95% CI ‐0.20 to 0.10)); very low‐certainty evidence for both outcomes. Only children were included in the study and the study did not report on any of our other clinically important outcomes. </p> <p><b>Nebulised azithromycin versus oral azithromycin</b> </p> <p>We were unable to include any of the data into our analyses and have reported findings directly from the paper; we graded all evidence as being of very low certainty. The authors reported that there was a greater mean change in FEV<sub>1</sub> % predicted at one month in the nebulised azithromycin group (P &lt; 0.001). We are uncertain whether there was a change in <i>P aeruginosa</i> count. </p> <p><b>Weekly azithromycin versus daily azithromycin</b> </p> <p>There is probably a lower mean change in FEV<sub>1</sub> % predicted at six months in the weekly group compared to the daily group (MD ‐0.70, 95% CI ‐0.95 to ‐0.45) and probably also a longer period of time until first exacerbation in the weekly group (MD 17.30 days, 95% CI 4.32 days to 30.28 days). Gastrointestinal side effects are probably more common in the weekly group and there is likely no difference in admissions to hospital or QoL. We graded all evidence as moderate certainty. </p> </section> <section id="CD002203-sec-0007"> <h3 class="title" id="CD002203-sec-0007">Authors' conclusions</h3> <p>Azithromycin therapy is associated with a small but consistent improvement in respiratory function, a decreased risk of exacerbation and longer time to exacerbation at six months; but evidence for treatment efficacy beyond six months remains limited. Azithromycin appears to have a good safety profile (although a weekly dose was associated with more gastrointestinal side effects, which makes it less acceptable for long‐term therapy), with a relatively minimal treatment burden for people with CF, and it is inexpensive. A wider concern may be the emergence of macrolide resistance reported in the most recent study which, combined with the lack of long‐term data, means we do not feel that the current evidence is strong enough to support azithromycin therapy for all people with CF. </p> <p>Future research should report over longer time frames using validated tools and consistent reporting, to allow for easier synthesis of data. In particular, future trials should report important adverse events such as hearing impairment or liver disease. More data on the effects of azithromycin given in different ways and reporting on our primary outcomes would benefit decision‐making on whether and how to give macrolide antibiotics. Finally, it is important to assess azithromycin therapy for people with CF who are established on the relatively new cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies which correct the underlying molecular defect associated with CF (none of the trials included in the review are relevant to this population). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002203-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002203-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002203-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002203-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002203-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002203-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002203-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002203-abs-0017">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002203-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002203-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002203-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002203-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002203-abs-0002" lang="en"> <h3>Treatment with macrolide antibiotics (including azithromycin) for people with cystic fibrosis </h3> <p><b>Review question</b> </p> <p>What are the effects of macrolide antibiotics in people with cystic fibrosis (CF) and infection of their airways? </p> <p><b>Key messages</b> </p> <p>‐ People with CF are more prone to chest infections caused by bacteria that can be hard to treat. </p> <p>‐ Macrolide antibiotics (such as azithromycin and clarithromycin) may lessen the effects of bacteria. </p> <p>‐ One macrolide antibiotic, azithromycin, can improve lung function at six months compared to a placebo (treatment with no active ingredient) and may reduce the risk of getting a flare‐up of lung infection. We are not sure whether a higher dose of azithromycin is any better than a lower dose, or if azithromycin when inhaled is any better than azithromycin when swallowed (oral). Oral azithromycin once a week compared to every day probably leads to less of an improvement in lung function, but there is probably a longer time to a flare‐up in the weekly group. </p> <p>‐ Current evidence does not support longer‐term use of azithromycin for all people with CF. </p> <p><b>Introduction</b> </p> <p>People with CF suffer from infections in their airways, often caused by the bug <i>Pseudomonas aeruginosa</i> , which is resistant to nearly all antibiotics that can be swallowed (oral). Macrolide antibiotics, e.g. azithromycin and clarithromycin, have no direct killing effect on <i>Pseudomonas aeruginosa</i>, but they may reduce the activity of these bacteria. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to discover whether the use of macrolide antibiotics (usually taken orally) affected the health of people with CF and whether these drugs have any side effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studiesthat looked at the effects of macrolide antibiotics in children and adults with CF and summarised the evidence. </p> <p><b>What did we find?</b> </p> <p>We found 14 studies, which put the total of 1467 children and adults into different treatment groups at random, which we included in this review. Eleven studies compared azithromycin to placebo, one compared two different doses of azithromycin (high versus low dose), one compared inhaled azithromycin to oral azithromycin, and one compared oral azithromycin once a week to once a day. </p> <p><b>Main results</b> </p> <p>We found that there was a slight improvement in lung function in people that were given azithromycin compared to a placebo at six months and also that the risk of a flare‐up of infection was lower. The risk of side effects (such as vomiting, diarrhoea and headache) was similar in both groups, as was the chance of a new infection with <i>Pseudomonas aeruginosa.</i> In terms of lung function and flare‐up of infection, we were unsure whether a higher dose of azithromycin is better than a lower dose (but only one study in children examined dose), or whether inhaled azithromycin is better than oral azithromycin. Taking oral azithromycin once a week compared to every day probably leads to less of an improvement in lung function, but there is probably a longer time to a flare‐up in the weekly group. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We were unable to combine all the study results because they were measured in different ways and at different time points; future trials should address this issue. Also, now that many people with CF are being treated with the new modulator therapies (e.g. elexacaftor‐tezacaftor‐ivacaftor), it is important to assess how macrolide antibiotics affect the health of these people. In the studies we found for this review, none of the people taking part were being treated with modulator therapies. </p> <p>We are able to report the results of the studies that compared azithromycin to placebo with certainty as the studies were well conducted and included a larger number of participants. The evidence from the studies comparing high and low doses or nebulised and oral azithromycin was much less certain because the studies were small and there was risk of bias in the way they were carried out. We were moderately certain of the results of the study comparing weekly azithromycin to daily azithromycin. </p> <p><b>How up to date is this evidence?</b> </p> <p>The studies we have reported are the most up to date we could find. We last searched for studies in November 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002203-sec-0154" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002203-sec-0154"></div> <h3 class="title" id="CD002203-sec-0155">Implications for practice</h3> <section id="CD002203-sec-0155"> <p>Azithromycin therapy is associated with a small but consistent improvement in respiratory function at six months and appears to have a good safety profile, although concerns over antimicrobial resistance remain pertinent<i>.</i> The three‐times‐a‐week dosing regimen used by most studies represents a relatively minimal treatment burden for people with cystic fibrosis (CF) and azithromycin is inexpensive. </p> <p>The evidence for treatment efficacy beyond six months remains limited. One study examined outcomes beyond six months and did not demonstrate a significant improvement in relative change in forced expiratory volume in one second (FEV<sub>1</sub>); however, other more pragmatic outcomes (need for oral antibiotics and remaining free of respiratory exacerbation) were in favour of azithromycin. </p> <p>A primary outcome for this review is pulmonary exacerbation and data from more recent studies (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>) support previous analysis suggesting a clinically meaningful difference in both the number of participants remaining free of exacerbation and the time to exacerbation (<a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>; <a href="./references#CD002203-fig-0009" title="">Analysis 1.4</a>). The primary outcome for <a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>, structural change seen on lung imaging, was not different between treatment groups. For <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>, although time to exacerbation was reduced in the azithromycin group, there was no reduction in recurrence of <i>Pseudomonas aeruginosa</i> airway infection (an important secondary outcome in that study). Longer‐term outcomes in these cohorts will provide important further information on the role of azithromycin, but as it stands, the evidence to support azithromycin prophylaxis is not strong even for infants diagnosed after newborn bloodspot screening. </p> <p>A wider concern for longer‐term use remains the emergence of macrolide resistance reported from epidemiological studies. Early reports suggest that this finding does not have a negative impact on clinical well‐being; however, it is a concern. If the mechanism of action of azithromycin relates to its anti‐staphylococcal activity, then there may be agents with better potency and a narrower spectrum of action against <i>Staphylococcus aureus</i> that are more appropriate to employ. </p> <p>For two studies, chronic <i>P aeruginosa</i> airway infection was not an inclusion criterion (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>), although one did enrol some participants with <i>P aeruginosa</i> infection at baseline (23% of the azithromycin group and 24% of the placebo group); but it is not clear if this was chronic infection or not (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). The fact that neither study demonstrated a statistically significant change in their primary outcome measure (relative change in FEV<sub>1</sub>) supports the argument that azithromycin therapy is not appropriate in this patient group. However, when data from these studies were incorporated into our meta‐analysis, they were consistent with previous studies and strengthened the finding of a small but significant improvement in FEV<sub>1</sub> after six months. </p> <p>In view of concerns over the emergence of macrolide‐resistant strains of <i>S aureus, non‐tuberculous mycobacterium</i> (NTM) and other bacteria, uncertainty remains about azithromycin therapy for all people with CF. Given the consistent finding of a short‐term improvement in FEV<sub>1</sub> in stable individuals, there may be an argument for use in those with poor respiratory condition despite maximal therapy or those who have problems adhering to therapies (given the relatively infrequent dosing regimen). However, the intervention has not been formally evaluated in either of these circumstances. </p> <p>A three‐times‐a‐week dose of 500 mg (250 mg if weight less than 40 kg) has been employed in three studies (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>), which together enroled 547 participants. These studies have contributed to the positive efficacy data reported in this review and the drug appeared to be well‐tolerated with this dosing regimen. A larger once‐a‐week dose was associated with significantly more gastrointestinal side effects (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>), which makes it less acceptable as a dosing strategy for long‐term therapy. </p> <p>In summary, longer‐term azithromycin therapy appears safe with some small but significant improvements in clinically relevant outcomes, most notably, time to pulmonary exacerbation and respiratory function at six months. Patients on azithromycin have less <i>Staphylococcus aureus</i> airway infection, but similar rates of <i>P aeruginosa</i> airway infection. </p> </section> <h3 class="title" id="CD002203-sec-0156">Implications for research</h3> <section id="CD002203-sec-0156"> <p>We have found high‐certainty evidence for the use of azithromycin in both adult and paediatric populations; since the review was last published in 2011, there have been two studies looking at the effects of macrolide antibiotics in infants identified via newborn screening (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>) and a further study in children aged eight to 18 years old (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). </p> <p>One of the main problems we encountered whilst summarising the data was the heterogeneity in the way that trials reported outcomes. For example, adverse events were recorded in most of the included studies, but were categorised and reported differently, making it difficult to combine results. The use of validated tools and consistent reporting in future research would allow for easier synthesis of data and therefore a more accurate representation of the true side effects of macrolide antibiotics. We found limited measurement or reporting of important adverse effects, such as hearing impairment or liver disease, and future research would benefit from including these outcomes. </p> <p>In the last update in 2011, we identified the need for longer‐term studies (<a href="./references#CD002203-bbs2-0077" title="SouthernKW , BarkerPM , Solis-MoyaA , PatelL . Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD002203. [DOI: 10.1002/14651858.CD002203.pub3]">Southern 2011</a>). In this version of the review, we include four new trials (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>), two of which followed participants for 18 and 36 months (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). Whilst these trials provided useful data, further long‐term studies (or longer‐term data from previous cohorts) would help to define the efficacy of macrolide antibiotics over a longer period of time and any side effects associated with longer‐term use. </p> <p>We have been able to report on different azithromycin regimens in this update (e.g. weekly versus daily dose, nebulised versus oral and low dose versus high dose). However, each comparison included only a single study, so we were uncertain of the effects of each regimen due to the certainty of the evidence being very low to moderate. More data on the effects of azithromycin given in different ways and reporting on our primary outcomes would benefit decision‐making on whether and how to give macrolide antibiotics. </p> <p>One important emerging effect of macrolide antibiotics is the possible acquisition of antibiotic resistance. Whilst antibiotic resistance was not an outcome in this review, we feel it is important to include it in future updates. </p> <p>In future updates, we also feel it would be important to consider a subgroup analysis to examine the effect of <i>P aeruginosa</i> at baseline. It is possible that the presence of <i>P aeruginosa</i> at the start of the study would be a confounding factor in terms of the effect of treatment with macrolide antibiotics. </p> <p>Finally, it is important to evaluate azithromycin therapy for people with CF who are established on CFTR modulator therapy, a relatively new therapy that corrects the underlying molecular defect associated with CF. None of the studies included in the review are relevant to this population. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002203-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002203-sec-0008"></div> <div class="table" id="CD002203-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ oral azithromycin compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral azithromycin versus placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> oral azithromycin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty</b> </p> <p><b>of the</b> </p> <p><b>evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted: mean change from baseline</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted </p> <p>ranged across control groups</p> <p>from ‐3.00% to 3.45%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention groups was </p> <p>3.97% higher</p> <p>(1.74 higher to 6.19 higher).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was also reported at other time points.</p> <p>At one month </p> <p>MD 3.99 % (95% CI 1.47 to 6.51); 2 studies, 229 participants</p> <p>At two months </p> <p>MD 2.37 % (95% CI 0.33 to 4.41); 5 studies, 310 participants</p> <p>At three months </p> <p>MD 2.70 % (95% CI ‐0.12 to 5.52); 2 studies, 225 participants</p> <p>At four months </p> <p>MD 5.19 % (95% CI ‐0.31 to 10.68); 2 studies, 123 participants</p> <p>At 12 months </p> <p>MD ‐0.13 (95% CI ‐4.96 to 4.70); 2 studies, 152 participants</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: time</b> </p> <p><b>to next exacerbation</b> </p> <p><b>Follow‐up: 6 to 36 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a longer time to exacerbation in the azithromycin group compared to the placebo group, HR 0.61 (95% CI 0.50 to 0.75). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>796</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The majority of participants in the included studies were 18 years or younger. Only 1 of the 4 studies included adults. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events: number of mild</b> </p> <p><b>treatment‐related</b> </p> <p><b>adverse events</b> </p> <p><b>Follow‐up: 6 to 18 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mild adverse events were common across the studies.</p> <p>There was no difference between groups in the reporting of diarrhoea, OR 1.43 (95% CI 0.81 to 2.50; 4 studies, 748 participants); sore throat, OR 0.85 (95% CI 0.57 to 1.26; 2 studies, 445 participants); rhinorrhoea, OR 0.91 (95% CI 0.59 to 1.38; 2 studies, 445 participants); headache, OR 0.84 (95% CI 0.56 to 1.27; 3 studies, 527 participants); abdominal pain, OR 0.93 (95% CI 0.61 to 1.41; 4 studies, 748 participants); constipation, OR 1.01 (95% CI 0.06 to 16.34; 1 study, 221 participants); fatigue, OR 0.66 (95% CI 0.39 to 1.09; 2 studies, 445 participants); nasal congestion, OR 1.07 (95% CI 0.72 to 1.58; 2 studies, 445 participants); vomiting, OR 0.88 (95% CI 0.56 to 1.40; 4 studies, 748 participants); hearing impairment, OR 1.13 (95% CI 0.07 to 18.31; 1 study, 185 participants); or tinnitus, OR 1.13 (95% CI 0.07 to 18.31; 1 study, 185 participants). </p> <p>Adverse events more common in the azithromycin group included nausea, OR 1.69 (95% CI 0.99 to 2.87; 2 studies, 445 participants); and wheezing, OR 2.13 (95% CI 1.07 to 4.25; 2 studies, 445 participants). </p> <p>Adverse events less common in the azithromycin group included cough, OR 0.46 (95% CI 0.30 to 0.69; 2 studies, 445 participants); and fever, OR 0.65 (95% CI 0.43 to 0.97; 3 studies, 527 participants). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no severe adverse events reported in any of the studies and moderate adverse events (resulting in discontinuation of the treatment) only occurred in 2 studies (1 participant in each). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations: admissions to hospital</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> <p>(76 to 191)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.61 (0.36 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported at 6 weeks and found no difference in hospital admissions, OR 0.88 (95% CI 0.17 to 4.55). </p> <p>A second study reported on hospital admissions at 18 months but found no difference between groups, OR 0.96 (95% CI 0.51 to 1.81). </p> <p>A further study reported the number of days in hospital and found that participants in the azithromycin group had fewer days in hospital than the placebo group (MD ‐6.30 days, 95% CI ‐10.63 to ‐1.97; 1 study, 130 participants). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA</b> </p> <p><b>Follow‐up: 12 months and over</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference in new acquisition of PA at 12 months and no difference in recurrence after first treatment quarter, HR 1.00 (95% CI 0.64 to 1.55). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At other time points, there were no differences between groups in new acquisition of PA, but numbers were low. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics: participants needing extra IV antibiotics</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> <p>(110 to 237)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.78 (0.49 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies also reported on the need for extra oral antibiotics and found that after 6 months there was a lower risk of needing extra antibiotics, OR 0.28 (95% CI 0.19 to 0.42; 3 studies, 527 participants). </p> <p>There was no difference at other time points.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL: mean change in quality of life measured with CFQ‐R</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in CFQ‐R total score was 0.1 (7.5) points.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in the azithromycin group was 1.6 points higher (0.61 lower to 3.81 higher).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few differences were found at other time points or with other measurement scales.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ‐R:</b> Cystic Fibrosis Questionnaire ‐ Revised; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>HR:</b> hazard ratio; <b>IV:</b> intravenous; <b>MD:</b> mean difference; <b>NA:</b> not applicable; <b>OR:</b> odds ratio; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once for indirectness as the majority of participants were 18 years or younger. Only 1 study included adults and it is unclear whether the results would be applicable to an adult population. </p> <p>b. Downgraded once for imprecision as most studies reported adverse events, but they were not reported in the same way and we could only include 4 in our meta‐analysis which limited our sample size; there was heterogeneity within the results. </p> <p>c. Downgraded once for imprecision due to a small number of participants from a single trial </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002203-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ high‐dose azithromycin compared to low‐dose azithromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose azithromycin versus low‐dose azithromycin for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> high‐dose azithromycin (15 mg/kg/day) </p> <p><b>Comparison:</b> low‐dose azithromycin (5 mg/kg/day) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of</b> </p> <p><b>the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Low‐dose azithromycin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>High‐dose Azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted:</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference in FEV<sub>1</sub> % predicted between baseline and 6 months in either group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were given as change from baseline within groups and we could not enter the data into our analyses. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: rate of exacerbations per child per month</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) rate of pulmonary exacerbations was 0.10 (0.30) per child/month in the low‐dose group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) rate of pulmonary exacerbations was 0.05 per child/month lower in the high‐dose group (0.20 lower to 0.10 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of children positive for PA over the course of the study was similar between groups, but no information was given on new acquisition. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>NA:</b> not applicable; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to risk of bias within the single included trial; particularly across the domains of allocation concealment, blinding and completeness of data. </p> <p>b. Downgraded once for imprecision due to low participant numbers from a single trial.</p> <p>c. Downgraded once for indirectness as the trial only included children. The results did not translate to an adult population. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002203-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ nebulised azithromycin compared to oral azithromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nebulised azithromycin versus oral azithromycin for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> nebulised azithromycin (70 mg once a day via jet nebuliser) </p> <p><b>Comparison:</b> oral azithromycin (500 mg in participants over 40 kg and 250 mg for those below 40 kg 3 times a week) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty</b> </p> <p><b>of the</b> </p> <p><b>evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral azithromycin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nebulised azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted: mean change from baseline</b> </p> <p><b>Follow‐up: 28 days</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> % predicted was 5.89% greater in the nebulised azithromycin group compared to the oral group (P &lt; 0.001). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results taken directly from the paper</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: time</b> </p> <p><b>to next exacerbation</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events:</b> number of </p> <p><b>treatment‐related</b> </p> <p><b>adverse events</b> </p> <p><b>Follow‐up: 28 days</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Productive cough was reported more frequently in the nebulised azithromycin group whilst diarrhoea, abdominal cramp, and heartburn were reported more frequently in the oral azithromycin group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported narratively from the paper.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA (</b>mean change in PA count (log<sub>10</sub> PA CFU/g sputum)) </p> <p><b>Follow‐up:</b> 28 days </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a greater decline in PA count in the nebulised azithromycin group. Treatment difference was ‐0.5 log<sub>10</sub> PA CFU/g sputum, P &lt; 0.001. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported directly from the paper.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL: change in PEDsQL‐4 scale</b> </p> <p><b>Follow‐up:</b> 28 days </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a greater mean change in PEDsQL‐4 scores in the nebulised azithromycin group compared to the oral azithromycin group, treatment effect ‐5.00, P &lt; 0.001. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A higher score indicates better QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFU:</b> colony forming units; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>NA:</b> not applicable; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>PEDsQL:</b> Pediatric Quality of Life Inventory; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to risk of bias within the single included trial; particularly across the domains of randomisation, allocation concealment, blinding and completeness of data </p> <p>b. Downgraded once for imprecision due to low participant numbers from a single trial</p> <p>c. Downgraded once for indirectness as the trial only included children. The results did not translate to an adult population. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002203-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings ‐ weekly azithromycin compared to daily azithromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Weekly versus daily azithromycin for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> weekly azithromycin (1200 mg weekly) </p> <p><b>Comparison:</b> daily azithromycin (250 mg daily) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty</b> </p> <p><b>of the</b> </p> <p><b>evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Daily azithromycin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Weekly azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted: mean change % predicted</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in FEV<sub>1</sub> was 3.10% predicted (0.80). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in the weekly azithromycin group was 0.70% predicted lower (0.95% lower to 0.45% lower). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: number of days to first exacerbation</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) number of days to first exacerbation was 70.00 days (44.80).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of days in the weekly azithromycin group was 17.30 days higher (4.32 higher to 30.28 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events: number of</b> </p> <p><b>treatment‐related</b> </p> <p><b>adverse events</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>324 per 1000</p> <p>(205 to 469)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.58 (0.85 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal adverse events were more likely in the weekly azithromycin group, OR 3.62 (95% CI 1.61 to 8.14). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations: mean number of hospital admissions</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) number of admissions was 0.60 (1.00).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of admissions in the weekly azithromycin group was the same as the daily group (0.25 lower to 0.25 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study stated only that PA was reported in 66% of participants at baseline and there was no difference between the groups. The percentage did not change over the course of the study. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL: change in CFQ score</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between groups across any domain except for the physical domain, where there was an improvement in the weekly group compared to the daily group of 8.2 points, P = 0.02. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ:</b> Cystic Fibrosis Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>NA:</b> not applicable; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once for imprecision due to low participant numbers in a single study</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002203-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002203-sec-0009"></div> <p>This review examines the use of macrolide antibiotics for the treatment of cystic fibrosis (CF) chest infection. </p> <section id="CD002203-sec-0010"> <h3 class="title" id="CD002203-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is a life‐limiting genetic condition which affects over 10,000 people in the UK (<a href="./references#CD002203-bbs2-0047" title="UK Cystic Fibrosis Trust. UK Cystic Fibrosis Registry Annual Data Report 2021. www.cysticfibrosis.org.uk/sites/default/files/2022-10/CFT_2021-Annual-Data-Report-WEB.pdf (accessed 12 June 2023).">CF Trust 2022</a>), over 30,000 in the USA (<a href="./references#CD002203-bbs2-0046" title="CF Foundation. Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report. www.cff.org/medical-professionals/patient-registry (accessed 12 June 2023).">CF Foundation 2022</a>), and more than 90,000 people worldwide. It is predominantly a disease of populations of Northern European descent (<a href="./references#CD002203-bbs2-0044" title="BellSC , MallMA , GutierrezH , MacekM , MadgeS , DaviesJC , et al. The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine2020;8(1):65-124.">Bell 2020</a>). The cystic fibrosis transmembrane regulator (CFTR) protein has an important role in the transport of salt and water across the surface of epithelia (<a href="./references#CD002203-bbs2-0045" title="BoucherRC . Molecular insights into the physiology of the 'thin film' of airway surface liquid. Journal of Physiology1999;516(Pt 3):631-8.">Boucher 1999</a>). In CF, abnormal CFTR function affects a number of organs in the body; however, the involvement of the airway has the most profound impact on quality of life (QoL) and survival. The defect in CF salt transport results in abnormal airway secretions, which leads to chronic airway infection and inflammation (<a href="./references#CD002203-bbs2-0061" title="MatsuiH , GrubbBR , TarranR , RandellSH , GatzyJT , DavisCW , et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition in the pathogenesis of cystic fibrosis airways disease. Cell1998;95(7):1005-15.">Matsui 1998</a>). Chronic bacterial infection in the airway is associated with an intense inflammatory process, which causes lung damage and further infection, eventually leading to respiratory failure. </p> <p>Characteristic organisms associated with lower airway infection in people with CF are, most notably, <i>Staphylococcus aureus</i> in the early course of the disease and <i>Pseudomonas aeruginosa</i> at a later stage (<a href="./references#CD002203-bbs2-0057" title="HutchisonML , GovanJR . Pathogenicity of microbes associated with cystic fibrosis. Microbes and Infection1999;1(12):1005-14.">Hutchison 1999</a>). Chronic airway infection with <i>P aeruginosa</i> in CF is characterised by the production of alginate which provides the bacteria with a protective mucoid coat. This biofilm may have an important role in the chronic airway infection that characterises CF. This is an unusual chronic airway condition as acute inflammatory cells (neutrophils) are the predominant mediators of the process. </p> <p>Treatment of chronic <i>P aeruginosa</i> infection in CF airways is challenging because of the limited number of antibiotics with direct killing activity. Quinolones, such as ciprofloxacin, are the only oral antibiotics available with direct killing activity against <i>P aeruginosa</i> . Other classes of anti‐pseudomonal antibiotics need to be given intravenously or aerosolised into the lungs. Increasing resistance of <i>P aeruginosa</i> to antibiotics is a significant challenge in the management of chronic airway infection in people with CF. </p> </section> <section id="CD002203-sec-0011"> <h3 class="title" id="CD002203-sec-0011">Description of the intervention</h3> <p>Macrolides are an orally available class of antibiotics that are often prescribed to treat community‐acquired pneumonia and skin infections. They have a broad spectrum of action against gram‐positive bacteria and some gram‐negative bacteria. The oldest and most widely used macrolide (in the UK) is erythromycin. Newer antibiotics in this class include clarithromycin, roxithromycin and azithromycin (this is quite a distinct molecule, called an azalide). Macrolides work by inhibiting protein synthesis in bacteria, but they can also impact on human cellular functions; care has to be taken when macrolides are prescribed alongside certain other drugs such as statins, theophyllines and the oral contraceptive pill. They have no direct killing activity against <i>P aeruginosa</i>. </p> </section> <section id="CD002203-sec-0012"> <h3 class="title" id="CD002203-sec-0012">How the intervention might work</h3> <p>Although macrolide antibiotics have direct killing properties against a number of characteristic CF pathogens, in particular <i>S aureus</i> and <i>Haemophilus influenzae,</i> there is the potential for these agents to have indirect actions against <i>P aeruginosa</i> and possibly other anti‐inflammatory actions that has generated the most interest in this class of antibiotic. </p> <p>In Japan, macrolides have been widely used since 1982 as a treatment for diffuse panbronchiolitis, a rare inflammatory lung condition affecting older Japanese people (<a href="./references#CD002203-bbs2-0056" title="HoibyN . Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax1994;49(6):531-2.">Hoiby 1994</a>). Infection with <i>P aeruginosa</i> in these people is associated with a poor outcome. There is some evidence (including one randomised controlled trial (RCT)) that, even at low doses, the long‐term use of macrolides has a beneficial effect on survival for people with this condition (<a href="./references#CD002203-bbs2-0059" title="KobayashiH , OhgakiN , TakedaH . Therapeutic possibilities for diffuse panbronchiolitis. International Journal of Antimicrobial Agents1993;3:S81-S86.">Kobayashi 1993</a>). This has been attributed to a reduction in factors (called virulence factors) that increase the activity of <i>P aeruginosa</i> . These virulence factors, such as the production of the mucoid biofilm, may be important for the pathogenicity of <i>P aeruginosa</i> in diffuse panbronchiolitis and CF. Laboratory studies also suggest that macrolides may have anti‐inflammatory properties (<a href="./references#CD002203-bbs2-0041" title="AndersonR , TheronAJ , FeldmanC . Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation1996;20(6):693-705.">Anderson 1996</a>; <a href="./references#CD002203-bbs2-0060" title="LabroMT . Anti-inflammatory activity of macrolides: a new therapeutic potential?Journal Antimicrobial Chemotherapeutics1998;41 Suppl B:37-46.">Labro 1998</a>; <a href="./references#CD002203-bbs2-0074" title="YanagiharaK , TomonoK , SawaiT , HirakataY , KadotaJ , Koga H et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine1997;155(1):337-42.">Yanagihara 1997</a>). </p> <p>Azithromycin is reported to show the most significant activity against the virulence factors of <i>P aeruginosa</i> (<a href="./references#CD002203-bbs2-0058" title="IchimiyaT , TakeokaK , HiramatsuK , HiraiK , YamasakiT , NasuM . The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy1996;42(3):186-91.">Ichimiya 1996</a>; <a href="./references#CD002203-bbs2-0062" title="MizukaneR , HirakataY , KakuM , IshiiY , FuruyaN , IshidaK , et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy1994;38(3):528-33.">Mizukane 1994</a>; <a href="./references#CD002203-bbs2-0063" title="MolinariG , GuzmanCA , PesceA , SchitoGC . Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. Journal of Antimicrobial Chemotherapy1993;31(5):681-8.">Molinari 1993</a>; <a href="./references#CD002203-bbs2-0067" title="RetsemaJ , GirardA , SchelklyW , ManousosM , AndersonM , BrightG , et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy1987;31(12):1939-47.">Retsema 1987</a>). The pharmacokinetics of azithromycin (an azalide) are fairly unique with considerable intracellular uptake and slow excretion (through the liver). The high tissue concentrations and long half‐life of azithromycin means that infrequent dosing schedules (for example, three times a week) are possible, making it an attractive oral therapy for people with CF (<a href="./references#CD002203-bbs2-0043" title="BallAP . Azithromycin: an interim analysis. Journal of International Medical Research1991;19(6):446-50.">Ball 1991</a>). </p> </section> <section id="CD002203-sec-0013"> <h3 class="title" id="CD002203-sec-0013">Why it is important to do this review</h3> <p>Macrolide antibiotics are well‐tolerated and relatively inexpensive; however, their increasingly widespread use has resulted in the emergence of resistant bacteria (in particular macrolide‐resistant <i>S aureus</i>) (<a href="./references#CD002203-bbs2-0053" title="HansenCR , PresslerT , HoibyN , JohansenHK . Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. Journal of Cystic Fibrosis2009;8(1):58-62.">Hansen 2009</a>; <a href="./references#CD002203-bbs2-0064" title="PhaffSJ , TiddensHA , VerbrughHA , OttA . Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. Journal of Antimicrobial Chemotherapy2006;57(4):741-6.">Phaff 2006</a>; <a href="./references#CD002203-bbs2-0073" title="Tramper-StrandersGA , WolfsTF , FleerA , KimpenJL , van derEntCK . Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatric Infectious Disease Journal2007;26(1):8-12.">Tramper‐Stranders 2007</a>). It is critical therefore that the efficacy and safety of macrolide therapy for CF are examined in a systematic manner; this is an updated review (<a href="./references#CD002203-bbs2-0075" title="SouthernKW , BarkerPM , SolisA . Macrolide antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database of Systematic Reviews2003, Issue 2. Art. No: CD002203. [DOI: 10.1002/14651858.CD002203]">Southern 2003</a>; <a href="./references#CD002203-bbs2-0076" title="SouthernKW , BarkerPM , SolisA . Macrolide antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database of Systematic Reviews2004, Issue 1. Art. No: CD002203. [DOI: 10.1002/14651858.CD002203.pub2]">Southern 2004</a>; <a href="./references#CD002203-bbs2-0077" title="SouthernKW , BarkerPM , Solis-MoyaA , PatelL . Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD002203. [DOI: 10.1002/14651858.CD002203.pub3]">Southern 2011</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002203-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002203-sec-0014"></div> <p>To assess the potential effects of macrolide antibiotics on clinical status in terms of benefit and harm in people with CF. If we were able to demonstrate benefit, we planned to assess the optimal type, dose and duration of macrolide therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002203-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002203-sec-0015"></div> <section id="CD002203-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002203-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs, published or unpublished. We planned to include quasi‐RCTs (e.g. alternate allocation and stratification), if there were no significant baseline differences between intervention and control groups. Cross‐over trials were eligible for inclusion if there was evidence of a sufficient washout period. If the washout period was shorter than three months and if baseline characteristics were not significantly different for intervention and control groups, then we included data from the first arm only. </p> </section> <section id="CD002203-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants diagnosed with CF. If two disease‐causing genetic mutations were not recognised, participants were required to have a positive sweat test and clinical features consistent with CF. </p> </section> <section id="CD002203-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Short‐term or long‐term (greater than 12 months) use of a macrolide antibiotic compared to controls who receive placebo, another antibiotic class, another macrolide or the same macrolide at a different dose. </p> </section> <section id="CD002203-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We planned to assess the following outcome measures.</p> <section id="CD002203-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002203-list-0001"> <li> <p>Lung function (per cent (%) predicted values for age, height and gender expressed as either absolute post treatment data, absolute change or relative change) </p> <ol id="CD002203-list-0002"> <li> <p>forced expiratory volume in one second (FEV<sub>1</sub>) </p> </li> <li> <p>forced vital capacity (FVC)</p> </li> <li> <p>non‐routine tests (e.g. thoracic gas volume (TGV), airway conductance (Gaw) and lung clearance index (LCI)) </p> </li> </ol> </li> <li> <p>Pulmonary exacerbation (protocol defined or physician determined)</p> <ol id="CD002203-list-0003"> <li> <p>number of participants free of exacerbation</p> </li> <li> <p>time to first exacerbation</p> </li> </ol> </li> <li> <p>Survival</p> </li> </ol> </p> </section> <section id="CD002203-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002203-list-0004"> <li> <p>Adverse effects</p> <ol id="CD002203-list-0005"> <li> <p>mild (defined as transient and treatment continued)</p> </li> <li> <p>moderate (generally treatment discontinued)</p> </li> <li> <p>severe (life‐threatening or seriously debilitating)</p> </li> </ol> </li> <li> <p>Number of days in hospital</p> </li> <li> <p>Acquisition or eradication of significant CF pathogens</p> <ol id="CD002203-list-0006"> <li> <p><i>P aeruginosa</i> </p> </li> <li> <p><i>S aureus</i> (including methicillin‐resistant <i>S aureus</i> (MRSA)) </p> </li> <li> <p><i>H influenzae</i> </p> </li> <li> <p>other significant pathogens</p> </li> </ol> </li> <li> <p>Additional treatment required (courses or days of treatment)</p> <ol id="CD002203-list-0007"> <li> <p>oral antibiotics</p> </li> <li> <p>intravenous (IV) antibiotics</p> </li> <li> <p>oral steroids</p> </li> <li> <p>any other medical CF therapy</p> </li> </ol> </li> <li> <p>Development of allergic bronchopulmonary aspergillosis (ABPA)</p> </li> <li> <p>Nutritional markers (e.g. weight and body mass index (BMI))</p> </li> <li> <p>Liver disease (as defined by any new clinical, radiographic or biochemical evidence of CF‐related liver disease) </p> </li> <li> <p>QoL (as measured by a valid disease‐specific QoL tool (e.g. Cystic Fibrosis Questionnaire ‐ Revised (CFQ‐R))) (<a href="./references#CD002203-bbs2-0065" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>) </p> </li> <li> <p>Changes in treatment burden (as measured by a disease‐specific tool e.g. treatment burden domain of the CFQ‐R (<a href="./references#CD002203-bbs2-0065" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) </p> </li> <li> <p>Changes in inflammatory markers</p> <ol id="CD002203-list-0008"> <li> <p>broncho‐alveolar lavage (BAL) samples</p> </li> <li> <p>serum samples</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD002203-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD002203-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies from the Group's Cystic Fibrosis Trials Register using the term: macrolide. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books from relevant conferences, including three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference, and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis Group <a href="https://cf.cochrane.org/cystic-fibrosis-trials-register" target="_blank">website</a>. </p> <p>Date of last search of the CF Register: 2 November 2022</p> <p>We also searched two online trials registries:</p> <p> <ul id="CD002203-list-0009"> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>): searched 9 November 2022; </p> </li> <li> <p>WHO ICTRP (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>): searched 9 November 2022. </p> </li> </ul> </p> <p>For details of our search strategies, please see <a href="./appendices#CD002203-sec-0160">Appendix 1</a>. </p> </section> <section id="CD002203-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We contacted principal investigators, known to work in the field for unpublished or follow‐up data. We also approached pharmaceutical companies that manufacture macrolide antibiotics (last contacted May 2010). </p> <p>We checked the reference lists of included studies for further relevant studies but did not find any additional references. </p> </section> </section> <section id="CD002203-sec-0026"> <h3 class="title" id="CD002203-sec-0026">Data collection and analysis</h3> <section id="CD002203-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For the 2011 update of this review, three authors (KS, PB and LP) independently selected studies to be included in the review; for the 2023 update, this was done by two authors (SS and DK). They resolved any disagreement through discussion with arbitration from a third author (KS or AS). </p> </section> <section id="CD002203-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For the 2011 update, three authors (KS, PB and LP) independently extracted data from included studies using standard data collection forms. For the 2023 update, two authors (SS and DK) independently extracted data and entered these into the review software (<a href="./references#CD002203-bbs2-0068" title="Review Manager Web (RevMan Web). Version 6.3. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.">RevMan Web 2023</a>). </p> <p>The authors considered outcomes to be short‐term if they were measured at the end of a treatment period up to 12 months. They considered outcomes to be long‐term if the treatment period was over 12 months or if there were more than three months between the end of the treatment and the measurement. The authors did not consider long‐term outcome measures for cross‐over studies. </p> <p>The authors grouped outcome data into those measured at one, two, three, four, six and 12 months (annually thereafter). They also included outcome data recorded at other time periods. </p> <p>Study groups sometimes reported the same outcome measure differently. For example, the need for additional oral antibiotics could be presented as a dichotomous outcome (number of participants who received additional oral antibiotics) or as a continuous outcome (number of courses or number of days). In these cases, the review authors contacted the primary investigators to request further data for the meta‐analysis. One of the primary outcomes was the relative change from the baseline in FEV<sub>1</sub> % predicted (calculated as (baseline minus post‐intervention) divided by baseline multiplied by 100). If papers reported FEV<sub>1</sub> % predicted as absolute change, the review authors contacted the primary investigators for further data to include in the meta‐analysis. </p> </section> <section id="CD002203-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the 2011 update, three authors (KS, PB and LP) independently assessed the risk of bias for each included study using the original Cochrane risk of bias tool (<a href="./references#CD002203-bbs2-0054" title="HigginsJP , AltmanDG , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). For the 2023 update, two authors (SS and DK) assessed the risk of bias using the same tool as described in a later version of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002203-bbs2-0055" title="Higgins JP AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). In particular, the authors examined the process of randomisation (allocation and generation), the degree of blinding in the study, whether outcome data were complete (the description of participants lost to follow‐up and those excluded from the study), selective outcome reporting and any other potential sources of bias. They recorded these factors in a risk of bias table for each study and assessed the risk of bias as high, low or uncertain. </p> </section> <section id="CD002203-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcome measures, the authors calculated a pooled estimate of the treatment effect for each outcome across studies using the pooled odds ratio (OR) and 95% confidence intervals (CIs) as a treatment effect estimate. </p> <p>For continuous outcomes, they recorded either mean change from baseline for each group or mean post treatment or intervention values and standard deviation (SD) for each group (they converted standard errors (SEs) to SDs). The authors calculated a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs. </p> </section> <section id="CD002203-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>When outcomes were presented in different forms, the authors have reported both and have approached primary investigators in order to obtain a single outcome. The review authors have reported results at (for continuous data) or after (for dichotomous data) set time periods of the interventions. In this way, they have been able to examine for changes over time and for heterogeneity. For adverse events, they combined all data regardless of the time period of the study. </p> <p>The review authors considered data from cross‐over studies for this review, although this study design may not be ideal for a condition when the intervention could potentially have a long‐standing impact on disease progression. If a washout period was not reported (or was reported as less than three months), providing there were no significant differences in the baseline characteristics of both groups, the review authors only considered data from the first arm of the study and compared these as for a parallel‐design study. They included data for dichotomous outcomes (such as adverse events and number of participants free from pulmonary exacerbation) as a direct comparison of the two arms, although this undervalues the power of the cross‐over design (<a href="./references#CD002203-bbs2-0048" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine2002;21(15):2131-44. [DOI: 10.1002/sim.1205]">Curtin 2002a</a>; <a href="./references#CD002203-bbs2-0049" title="CurtinF , ElbourneD , AltmanDG . Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine2002;21(15):2145-59. [DOI: 10.1002/sim.1206]">Curtin 2002b</a>; <a href="./references#CD002203-bbs2-0050" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover. Statistics in Medicine2002;21(15):2161-73. [DOI: 10.1002/sim.1207]">Curtin 2002c</a>). </p> </section> <section id="CD002203-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>In order to allow an intention‐to‐treat (ITT) analysis, the review authors sought data on the number of participants for each outcome event by allocated treated group, irrespective of compliance and whether the participant was later thought to be ineligible or otherwise excluded from treatment or follow‐up. If any data were missing or unclear, they contacted the primary investigators for clarification. For one study, investigators reported the primary outcome at various time points, but only in a figure (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). Subsequent individual patient data (IPD) provided by the authors did not contain data from all time points, so the review authors calculated these by measuring the figure (using a formula to convert the CI to SD). </p> </section> <section id="CD002203-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>The review authors examined heterogeneity through visual examination of the combined data presented in the forest plots and, more specifically, at the overlap of confidence limits. They also assessed heterogeneity by considering the I<sup>2</sup> statistic together with Chi<sup>2</sup> (<a href="./references#CD002203-bbs2-0051" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). </p> <p>They considered values of I² indicative of levels of heterogeneity as follows.</p> <p> <ol id="CD002203-list-0010"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ol> </p> </section> <section id="CD002203-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Where possible, the authors compared outcomes described in the protocol for each included study with those reported in the full‐text papers. If protocols were not available, the authors wrote to the primary investigators requesting the protocol; and, if that was not available, they compared the outcomes listed in the 'Methods' section of the full paper to the 'Results' section. If the published papers reported negative findings either only partially or not at all, the authors approached the primary investigators for those data. </p> <p>The authors also assessed the studies for publication bias (often characterised by presentation at a conference with no subsequent peer‐reviewed publication). </p> </section> <section id="CD002203-sec-0035"> <h4 class="title">Data synthesis</h4> <p>The review authors employed a fixed‐effect model to analyse data from the included studies as they did not consider these to be heterogeneous. </p> <p>If the authors had identified significant heterogeneity (I<sup>2</sup> greater than 60%) they planned to investigate the possible reasons for this. If they concluded the differences in the studies indicated that a random‐effects analysis would be more appropriate, they planned to repeat the original analysis using a random effects model and to compare the results from both the fixed‐effect and random‐effects analyses. They planned to document the differences in the studies and explain the rationale for any random‐effects analysis. </p> </section> <section id="CD002203-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>When considering the possible mechanism of action of macrolide antibiotics, subgroup analysis may be appropriate, particularly when considering individuals with and without chronic airway infection (most commonly with <i>P aeruginosa</i>). A number of investigators have reported data independently for these groups, although this is hampered by a clear and consistent definition of chronic airway infection. </p> </section> <section id="CD002203-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>The original review version planned to conduct a sensitivity analysis based on the methodological quality of studies, as assessed by methods described by <a href="./references#CD002203-bbs2-0070" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408-12.">Schulz 1995</a>. In the current review version, the review authors used the original Cochrane risk of bias tool to assess any risk of bias within the included studies and conducted a sensitivity analysis for outcomes where they were able to combine data from more than four studies (<a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>; <a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>; <a href="./references#CD002203-fig-0009" title="">Analysis 1.4</a>; <a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>; <a href="./references#CD002203-fig-0018" title="">Analysis 1.13</a>; <a href="./references#CD002203-fig-0019" title="">Analysis 1.14</a>) by excluding those studies with judgements of a high risk of bias for any domain assessed. </p> </section> <section id="CD002203-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The authors presented a summary of findings table for each comparison that they included in the review with the following outcomes. </p> <p> <ol id="CD002203-list-0011"> <li> <p>Change from baseline in FEV<sub>1</sub> % predicted at up to six months; </p> </li> <li> <p>Time to next pulmonary exacerbation (clinician‐ or protocol‐defined) at up to six months; </p> </li> <li> <p>Number of treatment‐related adverse events at up to six months;</p> </li> <li> <p>Hospitalisations at up to six months;</p> </li> <li> <p>New acquisition of CF pathogens (e.g. <i>P aeruginosa, Mycobacterium abscessus)</i> at up to 12 months; </p> </li> <li> <p>Need for additional antibiotics (oral, IV or inhaled) at up to six months;</p> </li> <li> <p>Change from baseline in a validated QoL score (e.g. CFQ‐R or CFQoL) at up to six months.</p> </li> </ol> </p> <p>For each outcome, they reported the illustrative risk with and without the intervention and the magnitude and direction of effect. For dichotomous outcomes, they reported absolute and corresponding risk as an OR (95% CI). For continuous data, they reported the absolute and corresponding risk as MD (95% CI). They also presented the number of studies contributing to the outcome and the number of participants (<a href="./references#CD002203-bbs2-0071" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022a</a>). </p> <p>The authors used GRADE to assess the certainty of the body of evidence for each outcome in the summary of findings tables (<a href="./references#CD002203-bbs2-0072" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022b</a>). They assessed the certainty of the evidence based on five domains: the risk of bias within the studies contributing to the outcome; relevance to the population of interest (indirectness); unexplained heterogeneity or inconsistency; imprecision of the results; and risk of publication bias. As a starting point, the authors assessed all the evidence as being at high certainty but downgraded once if the risk of bias was serious and twice if it was very serious across the five domains. They assessed each outcome individually and gave it a high, moderate, low or very low rating for the certainty of evidence. Where they downgraded the certainty of the evidence, they described their reasons and supporting information for their decisions in the footnotes for each summary of findings table. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002203-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002203-sec-0039"></div> <section id="CD002203-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD002203-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified a total of 124 publications (abstracts, papers and one thesis) after removal of duplicates. We excluded 20 records based on screening of title and abstract as they did not meet the inclusion criteria. Of the remaining 104 records relating to 40 individual studies, we included 14 studies (60 references) and excluded 20 studies (34 references). Six studies (10 references) are awaiting classification until further information is available. We have documented the process of study selection in a PRISMA diagram (<a href="#CD002203-fig-0001">Figure 1</a>) and present details of the included and excluded studies in the tables (<a href="./references#CD002203-sec-0175" title="">Characteristics of included studies</a>; <a href="./references#CD002203-sec-0176" title="">Characteristics of excluded studies</a>; <a href="./references#CD002203-sec-0177" title="">Characteristics of studies awaiting classification</a>). </p> <div class="figure" id="CD002203-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD002203-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD002203-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD002203-sec-0043"> <h5 class="title">Trial Design</h5> <p>All 14 included studies examined azithromycin as an intervention for CF (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Two were cross‐over studies (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>) and the remainder were of parallel design (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> <p>Out of the 14 included studies, 10 were multicentre studies conducted across different countries. Three studies were conducted in Australia and New Zealand (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>); one was conducted in France (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>); one was conducted in Germany and Switzerland (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>); one was conducted in the UK (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>); and four studies were conducted in the USA (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). The remaining four studies were single‐centre and conducted in India (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>); Iran (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>); Northern Ireland (<a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>); and Israel (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>). </p> <p>Duration of the intervention ranged from 28 days (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>) to 36 months (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). </p> </section> <section id="CD002203-sec-0044"> <h5 class="title">Participants</h5> <p>All studies enroled people with a confirmed diagnosis of CF. The number of participants ranged from 17 (<a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>) to 260 (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). In total, 1467 children and adults with CF have been included in these studies. </p> <p>Six studies enroled only children (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>), one study enroled only adults (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>), and the remaining seven studies enroled both adults and children (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). </p> <p>Most of the studies reported presence or absence of <i>P aeruginosa</i> airway infection at baseline (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). Baseline <i>P aeruginosa</i> status was not mentioned in four studies (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Presence (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>) or absence (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) of <i>P aeruginosa</i> were important entry criteria in three studies. </p> </section> <section id="CD002203-sec-0045"> <h5 class="title">Interventions</h5> <p>All the included studies reported on the effects of azithromycin as the intervention. Investigators in 11 studies compared oral azithromycin to matched placebo. One study administered a weight‐dependent dose ranging from 500 mg to 1250 mg azithromycin once a week (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>); one study gave 250 mg azithromycin twice a week (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>); five studies gave between 250 mg and 500 mg azithromycin three times a week (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); and two studies gave 250 mg azithromycin daily (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Two studies on young children gave 10 mg/kg body weight as an oral suspension three times a week (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). In <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>, participants in both groups also received standardised nebulised therapy with tobramycin for inhalation solution (TIS) (300 mg twice a day) for 28 days and a second course of TIS at three weeks if the <i>P aeruginosa</i> culture remained positive. Subsequently, participants were given a further course of TIS at the beginning of each quarter when samples were positive (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). One study compared high‐dose and low‐dose regimens. The intervention group received the high dose (15 mg/kg/day) whilst the control group received the low dose (5 mg/kg/day) (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). A further study compared a once‐weekly azithromycin (1200 mg) with a daily dosing regimen (250 mg daily) (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). The final study compared 70 mg of nebulised azithromycin diluted in 4 mL of 0.9% sodium chloride once a day to 250 mg of oral azithromycin three times a week (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). </p> </section> <section id="CD002203-sec-0046"> <h5 class="title">Outcomes</h5> <p>A total of 13 studies reported on measures of lung function including FEV<sub>1</sub>, FVC and forced expiratory flow at 25–75% of FVC (FEF<sub>25-75</sub>) over the course of the study (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). The remaining study included infants and children up to the age of 36 months and spirometric lung function was not measured; the primary outcome for this study was the time to first pulmonary exacerbation (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). A number of studies have measured and reported pulmonary exacerbations, but the measurements varied with studies reporting either total number of exacerbations during the study or time to next exacerbation. Nine studies reported on the number of participants who experienced an exacerbation either as a total number (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) or as a rate (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). The Wolter study reported on the number of participants who received IV antibiotics for an exacerbation (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Time to first pulmonary exacerbation was also reported as an outcome in five studies in total (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). </p> <p>Except for <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>, all the included studies reported on adverse events; seven reported hospitalisations (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>) and 11 reported on the acquisition of <i>P aeruginosa</i> (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Steinkamp reported the number of participants still positive for <i>P aeruginosa</i> at the end of the study (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). In 10 studies, investigators reported the acquisition of other pathogens including <i>S aureus</i> , <i>H influenzae</i> , MRSA, <i>B cepacia</i> and non‐tuberculous mycobacteria (NTM) (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> <p>Eight studies reported whether additional antibiotic courses were needed during the study, either IV antibiotics (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>), oral antibiotics (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>), or inhaled antibiotics (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). None of the studies reported on the need for additional steroids during the study. Only one study included development of allergic bronchopulmonary aspergillosis (ABPA) as an outcome (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>) and none reported liver disease. </p> <p>Most studies reported on nutritional markers such as weight (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>) or BMI (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Similarly, almost all the studies reported some measure of QoL using a validated scale such as CFQ or CFQ‐R (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>), Steinkamp used a German version of CFQ (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>) and other scales included Pediatric Quality of Life Inventory (PEDsQL‐4) (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>), Cystic Fibrosis Respiratory Symptom Diary (CFRSD) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>), Chronic Respiratory Infection Symptom Score (CRISS) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>), or an unspecified scoring system (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Three studies did not report on QoL (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) and none of the studies looked specifically at treatment burden. Seven studies reported changes in inflammatory markers (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> </section> </section> <section id="CD002203-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies in total. Nine studies were not RCTs (<a href="./references#CD002203-bbs2-0016" title="AnsteadMI , KuhnRJ , HartfordLH , CraigmyleL , HalseyS , KangaJF . Effect of chronic azithromycin on lung function in cystic fibrosis. Pediatric Pulmonology1999;28 Suppl 19:283-4. ">Anstead 1999</a>; <a href="./references#CD002203-bbs2-0019" title="AppEM , KonigA , DuffnerK , BaumannU , KingM , von derHardtH . The effects of azithromycin therapy on sputum inflammation in CF lung disease [abstract]. American Journal of Respiratory and Critical Care Medicine2000;161(3 Suppl):A758. [CFGD REGISTER: MA2d] BaumannU , AppE , KingM , FischerJ , ZimmermannT , SextroW , et al. Low-dose azithromycin therapy reaches sputum drug levels of potential antipseudomonal activity in cystic fibrosis patients. Journal of Cystic Fibrosis2002;1(Suppl 1):S130. [CFGD REGISTER: MA2c] BaumannU , AppEM , KonigA , SextroW , MatthysH , von derHardtH . Sputum DNA under long-term therapy with azithromycin. In: Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 2000:164. [CFGD REGISTER: MA2a] BaumannU , FischerJJ , TummlerB , SextroW , AppEM , KingM , et al. Long-term low-dose therapy with azithromycin in CF. In: Proceedings of the 13th International Cystic Fibrosis Congress;2000 June 4-8; Stockholm. 2000:165. [CFGD REGISTER: MA2b] BaumannU , KingM , AppEM , TaiS , KonigA , FischerJJ , et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Canadian Respiratory Journal [Revue canadienne de pneumologie]2004;11(2):151-5. [CFGD REGISTER: MA2e] ">Baumann 2000</a>; <a href="./references#CD002203-bbs2-0026" title="JaffeA , FrancisJ , RosenthalM , BushA . Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet1998;351(9100):420. ">Jaffe 1998</a>; <a href="./references#CD002203-bbs2-0027" title="Jensen PØ, MoserC , PresslerT , KochC , HøibyN . Circulating phagocytes during zithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. Journal of Cystic Fibrosis2005;4(Suppl 1):S24. [CFGD REGISTER: MA16] ">Jensen 2005</a>; <a href="./references#CD002203-bbs2-0029" title="NickJA , MoskowitzSM , ChmielJF , ForssenAV , KimSH , SaavedraMT , et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Annals of the American Thoracic Society2014;11(3):342-50. [CFGD REGISTER: PI257g] ">Nick 2014</a>; <a href="./references#CD002203-bbs2-0030" title="OrdonezCL , StulbargM , GrundlandH , LiuJT , BousheyHA . Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatric Pulmonology2001;32(1):29-37. [CFGD REGISTER: MA7] ">Ordonez 2001</a>; <a href="./references#CD002203-bbs2-0031" title="PirzadaOM , TaylorCJ . Long term macrolide antibiotics improve pulmonary function in cystic fibrosis. Pediatric Pulmonology1999;28 Suppl 19:263. [CFGD REGISTER: MA1] ">Pirzada 1999</a>; <a href="./references#CD002203-bbs2-0032" title="PukhalskyAL , ShmarinaGV , KapranovNI , KokarovtsevaSN , Kashirskaja NJu, LubskayaTV . Immunoregulatory effect of a 14-membered ring macrolide antibiotic in cystic fibrosis patients. European Respiratory Journal2001;18(Suppl 33):126s. [CFGD REGISTER: IB44d] PukhalskyAL , ShmarinaGV , KapranovNI , KokarovtsevaSN , PukhalskayaD , KashirskajaNJ . Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators of inflammation2004;13(2):111-7. [CFGD REGISTER: IB44c] PukhalskyAL , ShmarinaGV , KaproanovNI , KashirskajaNJ , KokarovtsevaSN , Shabalova LA et al. Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis. Pediatric Pulmonology2001;32 Suppl 22:274. [CFGD REGISTER: IB44b] ShmarinaGV , PukhalskyAL , KashirskajaNJ , Research Centre for Medical Genetics MR. Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic). European Respiratory Journal2004;24(Suppl 48):P3758. [CFGD REGISTER: IB44a] ">Pukhalsky 2001</a>; <a href="./references#CD002203-bbs2-0033" title="RadionovitchAM , KashirskayaNJ , KapranovNI . Long-term low-dose therapy with macrolides in bronchopulmonary disease in Cystic Fibrosis (CF) pediatric patients. Journal of Cystic Fibrosis2005;4(Suppl 1):S31. [CFGD REGISTER: MA17] ">Radionovitch 2005</a>) and one study did not investigate a macrolide antibiotic (<a href="./references#CD002203-bbs2-0015" title="AaronS , VandemheenK , FerrisW , TullisE , HaaseD , BerthiaumeY , et al. Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial. Pediatric Pulmonology2005;40(Suppl 28):304. [CFGD REGISTER: PI198a] AaronS . Clinical evidence for combination antibiotic susceptibility testing (synergy testing). Pediatric Pulmonology2008;43(Suppl 1):157. [CFGD REGISTER: PI198c] AaronSD , VandemheenKL , FerrisW , FergussonD , TullisE , HaaseD , et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet2005;366(9484):463-71. [CFGD REGISTER: PI198b] ">Aaron 2005</a>). Two studies were pharmacokinetic studies of azithromycin in CF (<a href="./references#CD002203-bbs2-0020" title="BeringerP , HuynhKM , KriengkauykiatJ , BiL , HoemN , Louie S et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy2005;49(12):5013-7. [CFGD REGISTER: MA12b] BeringerP , KriengkauykiatJ , LouieS , GillM , HanE , WooM , et al. Controlled pharmacokinetic study of azithromycin in adult cystic fibrosis patients. Pediatric Pulmonology2004;38(Suppl 27):285. [CFGD REGISTER: MA12a] ">Beringer 2005</a>; <a href="./references#CD002203-bbs2-0021" title="CipolliM , CazzolaG , NovelliA , CassettaMI , FallaniS , MazzeiT . Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clinical Drug Investigation2001;21(5):353-60. [CFGD REGISTER: MA9] ">Cipolli 2001</a>). </p> <p>Many of the excluded studies were only presented in abstract form and in seven studies there was insufficient information to allow inclusion despite attempts to contact study investigators (<a href="./references#CD002203-bbs2-0017" title="AnsteadM , KuhnRJ , HalseyS , DohertyDE , D'SouzaN , KangaJF . Effect of azithromycin on lung function, sputum bacteriology, and sputum inflammatory markers in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A565. [CFGD REGISTER: MA8] ">Anstead 2001</a>; <a href="./references#CD002203-bbs2-0022" title="DionyssopoulouV , PerpatiG , StefanatouE , ChristodoulouE , KalatziE , ArmeniakouE , et al. Laboratory and clinical effect of long-term roxithromycin treatment in adult patients with cystic fibrosis [abstract]. Journal of Cystic Fibrosis2005;4(Suppl 1):S24. [CFGD REGISTER: MA15] ">Dionyssopoulou 2005</a>; <a href="./references#CD002203-bbs2-0023" title="DogruD , DalgicF , KiperN , OzcelikU , YalcinE , AslanAT , et al. Effect of clarithromycin on inflammatory markers in bronchoalveolar lavage fluid in cystic fibrosis: a randomised, placebo-controlled crossover trial. Journal of Cystic Fibrosis2004;3(Suppl 1):S21. [CFGD REGISTER: MA22a] DoğruD , DalgiçF , KiperN , OzçelikU , YalçinE , AslanAT , et al. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turkish Journal of Pediatrics2009;51(5):416-23. [CFGD REGISTER: MA22b] ">Dogru 2004</a>; <a href="./references#CD002203-bbs2-0024" title="ElmasryS , MokSS , BraithwaiteM , SofianopoulosS , ClarkD , FinlaysonF , et al. Adherence behaviour of adult cystic fibrosis (CF) patients to prescribed azithromycin. Journal of Cystic Fibrosis2010;9(Suppl 1):S24. [ABSTRACT NO.: 92] [CFGD REGISTER: MA27a] ElmasryS , MokSS , BraithwaiteM , SofianopoulosS , ClarkD , FinlaysonF , et al. Adherence behaviour of adult cystic fibrosis patients prescribed azithromycin. Respirology2010;15(Suppl 1):A26. [ABSTRACT NO.: TO 064] [CFGD REGISTER: MA27c] San MokS , BraithwaiteM , ClarkD , SofianopoulosS , ElmasryS , FinlaysonF , et al. An anti-inflammatory effect of azithromycin in cystic fibrosis. European Respiratory Journal2010 ;36 Suppl 54:Abstract no.: P4795. [CFGD REGISTER: MA27b] ">Elmasry 2010</a>; <a href="./references#CD002203-bbs2-0025" title="FrederiksenB , KochC , HoibyN , PresslerT . Clinical efficacy of clarithromycin in CF patients with chronic lung infection. In: Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna. 2001:P208. [CFGD REGISTER: MA4] ">Frederiksen 2001</a>; <a href="./references#CD002203-bbs2-0028" title="KessarisA , SouliM , InglezosI , KanellakopoulouK , ApostolopoulouF , GiamarellouE . Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization. The European Respiratory Journal2003;22 Suppl 45:514s. [CFGD REGISTER: MA13] ">Kessaris 2003</a>; <a href="./references#CD002203-bbs2-0034" title="SriramS , YoungJ , WaterhouseJC , BucknallCE , StackBH . The antinflammatory effect of clarithromycin in CF. Journal of Cystic Fibrosis2003;2 (Suppl 1):S52. [CFGD REGISTER: MA10] ">Sriram 2003</a>). One study investigated the effect of clarithromycin on ion transport across the nasal epithelium in mice as well as adults with CF (<a href="./references#CD002203-bbs2-0018" title="BarkerPM , GillieDJ , SchechterMS , RubinBK . Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. American Journal of Respiratory and Critical Care Medicine2005;171(8):868-71. [CFGD REGISTER: MA23b] NCT00205634. Macrolide antibiotic therapy for patients with cystic fibrosis. www.clinicaltrials.gov/ct2/show/NCT00205634 (date first posted 20 Sep 2005). [CFGD REGISTER: MA23a] ">Barker 2005</a>). </p> </section> <section id="CD002203-sec-0048"> <h4 class="title">Studies awaiting classification</h4> <p>Six studies are awaiting classification (<a href="./references#CD002203-bbs2-0035" title="EUCTR2019-003501-10-DK. Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003501-10-DK (first registered 22 Apr 2020). [CFGD REGISTER: PI351] ">EUCTR2019‐003501‐10‐DK</a>; <a href="./references#CD002203-bbs2-0036" title="HansenCR , PresslerT , OlesenHV , StorostenO , LerumB , Norskov-LauritsenN , et al. Azithromycin in combination with inhaled colimycin and oral ciprofloxacin used for intermittent pseudomonas aeruginosa colonization in cystic fibrosis patients: results from a Scandinavian study. Pediatric Pulmonology2015;50 Suppl 41:318. [ABSTRACT NO.: 336] [CFGD REGISTER: MA30] ">Hansen 2015</a>; <a href="./references#CD002203-bbs2-0037" title="NCT00298922. Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex. https://clinicaltrials.gov/ct2/show/NCT00298922 Accessed 9 january 2023. [CFGD: MA32]">NCT00298922</a>; <a href="./references#CD002203-bbs2-0038" title="EUCTR2006-003275-12-DK. Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2006-003275-12-DK (first registered 17 Apr 2007). [CFGD REGISTER: PI337b] NCT00411736. Scandinavian cystic fibrosis azithromycin study. clinicaltrials.gov/show/NCT00411736 (first registered 5 Dec 2006). [CFGD REGISTER: PI337a] ">NCT00411736</a>; <a href="./references#CD002203-bbs2-0039" title="PukhalskyA , ShmarinaG , PukhalskayaD , PerederkoL . Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? In: European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:216s. [CFGD REGISTER: IB93] ">Pukhalsky 2008</a>; <a href="./references#CD002203-bbs2-0040" title="No authors listed. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Japanese Journal of Antibiotics2013;66 Suppl A:27-31. [CFGD REGISTER: MA28c] PittmanJE , SkallandMS , SagelSD , RamseyBW , Mayer-HamblettN , Retsch-BogartGZ . Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis [Epub ahead of print 5 March 2022]. [CFGD REGISTER: MA31g] [DOI: 10.1016/j.jcf.2022.02.015]RobinsonP , SchechterMS , SlyPD , WinfieldK , SmithJ , BrennanS , et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2012;47(6):551-7. [CFGD REGISTER: MA28b] RobinsonP , SchwchterMS , SlyP , WinfieldK , BrennanS , SmithJ , et al. Clarithromycin therapy is not effective for the therapy of CF. Pediatric Pulmonology2011;46 Suppl 34:339. [ABSTRACT NO.: 351] [CFGD REGISTER: MA28a] ">Robinson 2011</a>). We have attempted to contact the authors of those studies presented as abstracts, but have not yet received any reply (<a href="./references#CD002203-bbs2-0036" title="HansenCR , PresslerT , OlesenHV , StorostenO , LerumB , Norskov-LauritsenN , et al. Azithromycin in combination with inhaled colimycin and oral ciprofloxacin used for intermittent pseudomonas aeruginosa colonization in cystic fibrosis patients: results from a Scandinavian study. Pediatric Pulmonology2015;50 Suppl 41:318. [ABSTRACT NO.: 336] [CFGD REGISTER: MA30] ">Hansen 2015</a>; <a href="./references#CD002203-bbs2-0039" title="PukhalskyA , ShmarinaG , PukhalskayaD , PerederkoL . Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? In: European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:216s. [CFGD REGISTER: IB93] ">Pukhalsky 2008</a>; <a href="./references#CD002203-bbs2-0040" title="No authors listed. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Japanese Journal of Antibiotics2013;66 Suppl A:27-31. [CFGD REGISTER: MA28c] PittmanJE , SkallandMS , SagelSD , RamseyBW , Mayer-HamblettN , Retsch-BogartGZ . Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis [Epub ahead of print 5 March 2022]. [CFGD REGISTER: MA31g] [DOI: 10.1016/j.jcf.2022.02.015]RobinsonP , SchechterMS , SlyPD , WinfieldK , SmithJ , BrennanS , et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2012;47(6):551-7. [CFGD REGISTER: MA28b] RobinsonP , SchwchterMS , SlyP , WinfieldK , BrennanS , SmithJ , et al. Clarithromycin therapy is not effective for the therapy of CF. Pediatric Pulmonology2011;46 Suppl 34:339. [ABSTRACT NO.: 351] [CFGD REGISTER: MA28a] ">Robinson 2011</a>). </p> <p><a href="./references#CD002203-bbs2-0035" title="EUCTR2019-003501-10-DK. Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003501-10-DK (first registered 22 Apr 2020). [CFGD REGISTER: PI351] ">EUCTR2019‐003501‐10‐DK</a> is a trial registration document for a multicentre, open‐label RCT of parallel design (<a href="./references#CD002203-bbs2-0035" title="EUCTR2019-003501-10-DK. Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-003501-10-DK (first registered 22 Apr 2020). [CFGD REGISTER: PI351] ">EUCTR2019‐003501‐10‐DK</a>). The aim of the study is to examine whether LCI increases due to increased inflammation from bacterial colonisation in the airways and if the length of treatment with antibiotics affects LCI outcome. It is a four‐arm study looking at different antibiotics (amoxicillin, flucloxacillin, clavulanic acid, dicloxacillin, sulfamethoxazole, trimetoprim, clarithromycin, rifampicin, doxycycline, fusidic acid, ciprofloxacin, linezolid, clindamycin, cefuroxim, cefalexin), but the intervention schedule is unclear and data for the macrolide antibiotics may not be available (no results posted to date). </p> <p><a href="./references#CD002203-bbs2-0036" title="HansenCR , PresslerT , OlesenHV , StorostenO , LerumB , Norskov-LauritsenN , et al. Azithromycin in combination with inhaled colimycin and oral ciprofloxacin used for intermittent pseudomonas aeruginosa colonization in cystic fibrosis patients: results from a Scandinavian study. Pediatric Pulmonology2015;50 Suppl 41:318. [ABSTRACT NO.: 336] [CFGD REGISTER: MA30] ">Hansen 2015</a> looked at whether the addition of azithromycin to inhaled colomycin and oral ciprofloxacin would prolong the <i>P aeruginosa</i>‐free interval after treatment. The study is only presented as an abstract and there is insufficient information regarding the study methods and intervention schedule, as well as uncertainty about whether results for macrolides can be separated out. </p> <p><a href="./references#CD002203-bbs2-0037" title="NCT00298922. Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex. https://clinicaltrials.gov/ct2/show/NCT00298922 Accessed 9 january 2023. [CFGD: MA32]">NCT00298922</a> is also only presented as a trial registration document with no full paper or results to include in this review. It is a double‐blind, placebo‐controlled study including 45 participants over the age of 18 with a confirmed diagnosis of CF. The intervention group received 500 mg oral azithromycin three times a week for 24 weeks compared to a placebo tablet three times a week. The primary outcome was change in FEV<sub>1</sub> % predicted, and secondary outcomes included changes in FVC, time until IV antibiotics, number of IV antibiotic treatment days, hospitalisations and body weight in addition to inflammatory markers (<a href="./references#CD002203-bbs2-0037" title="NCT00298922. Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex. https://clinicaltrials.gov/ct2/show/NCT00298922 Accessed 9 january 2023. [CFGD: MA32]">NCT00298922</a>). </p> <p>The review authors identified two trial registration documents for a multicentre Scandinavian study which included 45 participants over the age of one year (<a href="./references#CD002203-bbs2-0038" title="EUCTR2006-003275-12-DK. Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2006-003275-12-DK (first registered 17 Apr 2007). [CFGD REGISTER: PI337b] NCT00411736. Scandinavian cystic fibrosis azithromycin study. clinicaltrials.gov/show/NCT00411736 (first registered 5 Dec 2006). [CFGD REGISTER: PI337a] ">NCT00411736</a>). Participants were given oral azithromycin either as a syrup for children under eight years old (40 mg/mL given in a single daily dose of 5 mg/kg/day) or as tablets for adults and children aged eight or over (250 mg tablets given every other day for participants weighing less than 40 kg and one tablet every day if weight was over 40 kg). The primary outcome was time to next airway colonisation with <i>P aeruginosa</i> and secondary outcomes included height, weight, lung function and bacteriology. No results have been posted and the review authors have been unable to find a full paper (<a href="./references#CD002203-bbs2-0038" title="EUCTR2006-003275-12-DK. Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study. trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2006-003275-12-DK (first registered 17 Apr 2007). [CFGD REGISTER: PI337b] NCT00411736. Scandinavian cystic fibrosis azithromycin study. clinicaltrials.gov/show/NCT00411736 (first registered 5 Dec 2006). [CFGD REGISTER: PI337a] ">NCT00411736</a>). </p> <p>A further study awaiting classification included 160 children with CF and 100 healthy controls (<a href="./references#CD002203-bbs2-0039" title="PukhalskyA , ShmarinaG , PukhalskayaD , PerederkoL . Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? In: European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:216s. [CFGD REGISTER: IB93] ">Pukhalsky 2008</a>). A total of 70 out of 160 children in the study with CF (43.8%) were either given azithromycin (500 mg orally three times per week (n = 48)), or prednisolone (0.3 mg/kg body weight every other day (n = 22)); the remaining 90 children with CF were not given any anti‐inflammatory therapy. The study investigators examined the plasma levels of adrenocorticotropic hormone (ACTH) and cytokines in children with CF and compared these to levels in children without CF (<a href="./references#CD002203-bbs2-0039" title="PukhalskyA , ShmarinaG , PukhalskayaD , PerederkoL . Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? In: European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:216s. [CFGD REGISTER: IB93] ">Pukhalsky 2008</a>). It is not clear if the study was randomised. </p> <p>The final study awaiting classification is a double‐blind, placebo‐controlled cross‐over RCT which included 18 participants and compared oral clarithromycin at a dose of 500 mg a day to placebo (<a href="./references#CD002203-bbs2-0040" title="No authors listed. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Japanese Journal of Antibiotics2013;66 Suppl A:27-31. [CFGD REGISTER: MA28c] PittmanJE , SkallandMS , SagelSD , RamseyBW , Mayer-HamblettN , Retsch-BogartGZ . Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis [Epub ahead of print 5 March 2022]. [CFGD REGISTER: MA31g] [DOI: 10.1016/j.jcf.2022.02.015]RobinsonP , SchechterMS , SlyPD , WinfieldK , SmithJ , BrennanS , et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2012;47(6):551-7. [CFGD REGISTER: MA28b] RobinsonP , SchwchterMS , SlyP , WinfieldK , BrennanS , SmithJ , et al. Clarithromycin therapy is not effective for the therapy of CF. Pediatric Pulmonology2011;46 Suppl 34:339. [ABSTRACT NO.: 351] [CFGD REGISTER: MA28a] ">Robinson 2011</a>). Outcomes include pulmonary function, QoL (CFQ teenage version, child version and parent version), pulmonary exacerbations and sputum inflammatory markers. The washout period for this RCT was shorter than the three months the review authors specified in their methods, and so they would only be able to include first‐arm data. The review authors contacted the study investigators for further information on 23 January 2023 (<a href="./references#CD002203-bbs2-0040" title="No authors listed. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Japanese Journal of Antibiotics2013;66 Suppl A:27-31. [CFGD REGISTER: MA28c] PittmanJE , SkallandMS , SagelSD , RamseyBW , Mayer-HamblettN , Retsch-BogartGZ . Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis [Epub ahead of print 5 March 2022]. [CFGD REGISTER: MA31g] [DOI: 10.1016/j.jcf.2022.02.015]RobinsonP , SchechterMS , SlyPD , WinfieldK , SmithJ , BrennanS , et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatric Pulmonology2012;47(6):551-7. [CFGD REGISTER: MA28b] RobinsonP , SchwchterMS , SlyP , WinfieldK , BrennanS , SmithJ , et al. Clarithromycin therapy is not effective for the therapy of CF. Pediatric Pulmonology2011;46 Suppl 34:339. [ABSTRACT NO.: 351] [CFGD REGISTER: MA28a] ">Robinson 2011</a>). </p> </section> </section> <section id="CD002203-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>In six of the 14 included studies, there was no apparent risk of bias (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) and for three studies there were minor concerns over reporting and baseline characteristics (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). These nine studies enroled the majority of participants included in this review (1302 out of 1467 total participants). In five studies, which contributed 165 of the 1467 total participants, there were significant concerns over the risk of bias across several domains (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>) (<a href="#CD002203-fig-0002">Figure 2</a>; <a href="#CD002203-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD002203-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD002203-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD002203-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD002203-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD002203-sec-0050"> <h4 class="title">Allocation</h4> <p>For 10 studies, the generation and concealment of allocation was undertaken in a correct and rigorous manner, leading to a low risk of bias (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). In some study reports, this information was not clear, but subsequent correspondence has clarified the situation. Four studies caused concern (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Two studies stated that sequence generation was randomised, but provided no details of allocation concealment, so we judged these to have an unclear risk of bias (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). Neither the method of randomisation nor any allocation concealment were described in the remaining two studies, and we judged the risk of bias to be unclear for this domain (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> </section> <section id="CD002203-sec-0051"> <h4 class="title">Blinding</h4> <p>The review authors deemed 11 of the studies to be at low risk of bias for blinding of participants, caregivers and outcome assessors as they employed identical packaging and matched tablets for colour, taste and number taken (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> <p>They deemed two of the studies to be at an unclear risk of bias (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). The Kabra study compared a high dose to a low dose of azithromycin, and it was not clear whether the participants were aware of their allocation or whether there was an attempt at blinding (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). The Maneshi study was open‐label and whilst for some outcomes this is unlikely to have biased the result, e.g. changes in <i>P aeruginosa</i> colonisation, other outcomes such as QoL and spirometry could have been affected by knowledge of allocation (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). </p> <p>One study did not attempt to match the placebo and intervention tablets, and they were different colours. Whilst the colour of the tablets (placebo tablets were coloured red and the intervention tablets were brown) was known to the pharmacy and not participants or investigators, there was speculation and the review authors have deemed the risk of bias to be high (<a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>). </p> </section> <section id="CD002203-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>The review authors judged three of the included studies to be at high risk of attrition bias (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>). The Kabra study did not employ an ITT analysis and only reported on a per‐protocol basis. More than 15% of participants were omitted from the analysis (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). In the Maneshi study, 25% of participants were lost to follow‐up and these were unequally spread between the two groups (10 participants in the control arm compared to five participants in the intervention arm) and no reasons were given (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). In the Rotschild study, no description of the three participants who dropped out of the study due to non‐compliance was available, and it is not clear to which groups these participants belonged; the review authors therefore deemed the risk of bias to be high (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>). </p> <p>The review authors judged the remaining 11 studies to be at low risk of attrition bias (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> </section> <section id="CD002203-sec-0053"> <h4 class="title">Selective reporting</h4> <p>Protocols were not available for all the included studies, but overall there was a good level of reporting of outcomes and the review authors have included aggregate data in this review. On some occasions, data were not fully reported, and the review authors contacted study investigators. They have subsequently been able to obtain most data, sometimes in the form of IPD. They assessed 12 included studies as being at low risk of bias from selective reporting because all outcomes listed in the methods section were reported in the results section (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a><a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). The review authors judged two studies to be at an unclear risk of bias from selective reporting (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). In the Caparros‐Martin study, investigators stated in the methods section that they would measure the time to next exacerbation, but in the results they listed only the mean number of exacerbations per year (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). Some data at intermediate time points in the Clement study were not reported in the results (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). </p> </section> <section id="CD002203-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies employed a cross‐over design, which may not be the ideal design for an intervention that potentially could have a significant impact on longer‐term disease progression (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>). However, both studies employed two‐month washout periods and there did not appear to be any carry‐over effects. Review authors have included data in the meta‐analysis from the first arm of the Equi study, as the baseline characteristics of both groups were similar, although we appreciate this loses some of the power of the cross‐over design (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>). We have therefore graded other risk of bias as low. </p> <p>The review authors graded the Kabra study as being at unclear risk of other bias, as there were more boys in the high‐dose group giving an imbalance in the population at baseline (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). Similarly, the review authors graded the Wolter study as being at an unclear risk of bias due to baseline differences in the intervention compared to the placebo group (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). They also graded the Rotschild study as being at an unclear risk of other bias, as investigators used a VAS scale which was not validated (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>). </p> <p>The Steinkamp study reduced the duration of the trial after commencement and the review authors have therefore assessed this as being at high risk of bias from other sources (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). </p> <p>The review authors graded the remaining 10 studies as being at low risk of bias from other sources (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). </p> </section> </section> <section id="CD002203-sec-0055"> <h3 class="title" id="CD002203-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD002203-tbl-0001"><b>Summary of findings 1</b> Summary of findings ‐ oral azithromycin compared to placebo</a>; <a href="./full#CD002203-tbl-0002"><b>Summary of findings 2</b> Summary of findings ‐ high‐dose azithromycin compared to low‐dose azithromycin</a>; <a href="./full#CD002203-tbl-0003"><b>Summary of findings 3</b> Summary of findings ‐ nebulised azithromycin compared to oral azithromycin</a>; <a href="./full#CD002203-tbl-0004"><b>Summary of findings 4</b> Summary of findings ‐ weekly azithromycin compared to daily azithromycin</a> </p> <p>We graded the certainty of the evidence for those outcomes included in the summary of findings tables. For the definitions of these gradings, please refer to the summary of findings tables (<a href="./full#CD002203-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD002203-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002203-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002203-tbl-0004">summary of findings Table 4</a>). </p> <p>We have only reported on the outcomes from our review that were included in the studies.</p> <section id="CD002203-sec-0056"> <h4 class="title">Oral azithromycin compared to placebo</h4> <p>There are 11 studies (1167 participants) included in this comparison (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). The certainty of evidence is presented in <a href="./full#CD002203-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD002203-sec-0057"> <h5 class="title">Primary outcomes</h5> <section id="CD002203-sec-0058"> <h6 class="title">1. Lung function</h6> <section id="CD002203-sec-0059"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Except for <a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>, the remaining 10 studies reported on the change from baseline in FEV<sub>1</sub> % predicted at various time points. </p> <p>Two studies reported change from baseline at one month (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>); data showed a slight difference favouring the azithromycin group (MD 3.99% predicted, 95% CI 1.47 to 6.51; 2 studies, 229 participants; I<sup>2</sup> = 0%; <a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>). At two months, we were able to include five studies in a meta‐analysis (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Results showed a slight difference between treatment groups favouring azithromycin (MD 2.37% predicted, 95% CI 95% CI 0.33 to 4.41; 5 studies, 310 participants; I<sup>2</sup> = 0%; <a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>; <a href="#CD002203-fig-0004">Figure 4</a>). The planned sensitivity analysis where authors excluded data from <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a> (the only study with a high risk of bias in any domain), showed no difference in the magnitude of effect. We were not able to include data from two studies in our analysis, but investigators from both studies reported that no changes were seen in FEV<sub>1</sub> % predicted in either group at two months (<a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>). </p> <div class="figure" id="CD002203-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV1 (% predicted)" data-id="CD002203-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV<sub>1</sub> (% predicted) </p> </div> </div> </div> <p>We found no difference between groups at three months (MD 2.70% predicted, 95% CI ‐0.12 to 5.52; 2 studies, 225 participants; I<sup>2</sup> = 0%; <a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>); or at four months (MD 5.19% predicted, 95% CI ‐0.31 to 10.68; 2 studies, 123 participants; I<sup>2</sup> = 0%; <a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>). At six months, there was a slight improvement in the azithromycin group compared to placebo (MD 3.97% predicted, 95% CI 1.74 to 6.19; 4 studies, 549 participants; high‐certainty evidence; I<sup>2</sup> = 5%; <a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). </p> <p>Two studies reported change from baseline at 12 months (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>) and found no difference between azithromycin and placebo (MD ‐0.13% predicted, 95% CI ‐4.96 to 4.70; 2 studies, 152 participants; I<sup>2</sup> = 0%; <a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>). </p> <p>The validity of this result was supported by the lack of heterogeneity as demonstrated by the I<sup>2</sup> values which were 0% for all time points except at six months (5% at this time point). We have presented this in a funnel plot (<a href="#CD002203-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD002203-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV1 (% predicted)" data-id="CD002203-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV<sub>1</sub> (% predicted) </p> </div> </div> </div> </section> <section id="CD002203-sec-0060"> <p><b>b. FVC</b></p> <p>Two studies reported percentage change from baseline of FVC (%) in the short term (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>) and found a slight difference favouring azithromycin at two months (MD 5.42%, 95% CI 1.79 to 9.05; 2 studies, 76 participants; I² = 77%; <a href="./references#CD002203-fig-0007" title="">Analysis 1.2</a>). There was no difference between groups at 12 months (MD 2.70%, 95% CI ‐2.88 to 8.28; 1 study, 82 participants; <a href="./references#CD002203-fig-0007" title="">Analysis 1.2</a>) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). </p> </section> </section> <section id="CD002203-sec-0061"> <h6 class="title">2. Pulmonary exacerbations</h6> <p>Pulmonary exacerbations (either protocol‐defined or physician‐determined) were recorded in a number of ways (including time to exacerbation and total number of exacerbations). </p> <section id="CD002203-sec-0062"> <p><b>Number of participants free from exacerbation</b></p> <p>Data from six studies allowed the calculation of the number of people free of exacerbation at reported time points between one and 12 months (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). Two studies reported at multiple time points (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>), while four studies reported at single time points (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). </p> <p>Only a single study reported results at one month (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>), finding that participants in the azithromycin group were more likely to be exacerbation‐free than those in the placebo group (OR 5.66, 95% CI 1.86 to 17.23; 1 study, 185 participants; <a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>). However, at two months (data from a six‐week study), <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a> found no difference between groups (OR 1.00, 95% CI 0.36 to 2.82; 1 study, 115 participants; <a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>). We were able to combine three‐month data from two studies and found more participants were exacerbation‐free in the azithromycin group at this time point (OR 2.72, 95% CI 1.49 to 4.99; 2 studies, 203 participants; I<sup>2</sup> = 32%; <a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>) (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). Four studies reported data at six months (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) and again showed that more participants were exacerbation‐free in the azithromycin group (OR 1.94, 95% CI 1.38 to 2.71; 4 studies, 609 participants; I² = 55%; <a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>). None of these studies had a high risk of bias in any domain, so the authors did not conduct the planned sensitivity analysis. Finally, only <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> reported data at 12 months which again showed more participants being exacerbation‐free than in the placebo group (OR 10.77, 95% CI 2.26 to 51.34; 1 study, 82 participants; <a href="./references#CD002203-fig-0008" title="">Analysis 1.3</a>). </p> <p>Considering the combined results for the number of participants who were free from exacerbation from all the studies, participants on azithromycin were more likely to be free of exacerbation with the data from one six‐week study being the exception (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>). However, data from one of the studies reporting at multiple time points showed more participants in the azithromycin group being exacerbation‐free at one and three months, but no difference at six months (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). </p> </section> <section id="CD002203-sec-0063"> <p><b>Time to first exacerbation</b></p> <p>Four studies reported on the time to first pulmonary exacerbation (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). All studies found a longer time to exacerbation in the azithromycin group compared to the placebo group (HR 0.61, 95% CI 0.50 to 0.75; 4 studies, 796 participants; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD002203-fig-0009" title="">Analysis 1.4</a>). None of these studies had a high risk of bias in any domain, so the authors did not conduct the planned sensitivity analysis. </p> </section> </section> <section id="CD002203-sec-0064"> <h6 class="title">3. Survival</h6> <p>There were no deaths reported in any of the included studies.</p> </section> </section> <section id="CD002203-sec-0065"> <h5 class="title">Secondary outcomes</h5> <section id="CD002203-sec-0066"> <h6 class="title">1. Adverse effects</h6> <p>All the included studies comparing oral azithromycin to placebo reported on adverse effects. All studies reported standard clinical and laboratory monitoring for adverse events, including liver function tests. Three studies assessed hearing (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). </p> <p>Two studies reported the overall number of adverse events (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>), which were no more frequent in the azithromycin group than the placebo group (OR 0.88, 95% CI 0.45 to 1.73; 2 studies, 153 participants; <a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>). Two studies reported the total number of "Respiratory, thoracic and mediastinal disorders" (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>); results showed slightly fewer events in the azithromycin group (OR 0.54, 95% CI 0.31 to 0.96; 2 studies, 336 participants; <a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>). </p> <section id="CD002203-sec-0067"> <p><b>a. Mild</b></p> <p>We defined mild adverse events as transient and not necessitating discontinuation of treatment. Two studies (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) reported a slight increased risk of wheezing (OR 2.13, 95% CI 1.07 to 4.25; 2 studies, 445 participants; <a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>) and a decrease in the number of participants experiencing cough with azithromycin (OR 0.46, 95% CI 0.30 to 0.69; 2 studies, 445 participants; <a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>). Three studies (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>) reported that participants in the azithromycin group were less likely to experience fever (OR 0.65, 95% CI 0.43 to 0.97; 3 studies, 527 participants; <a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>). </p> <p>No differences were reported between groups for any other listed adverse effects (<a href="./references#CD002203-fig-0010" title="">Analysis 1.5</a>): nausea (OR 1.69, 95% CI 0.99 to 2.87; 2 studies, 445 participants); diarrhoea (OR 1.43, 95% CI 0.81 to 2.50; 4 studies, 748 participants) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); sore throat (OR 0.85, 95% CI 0.57 to 1.26; 2 studies, 445 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); increased sputum (OR 0.67, 95% CI 0.37 to 1.20; 1 study, 82 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>); rhinorrhoea (OR 0.91, 95% CI 0.59 to 1.38; 2 studies, 445 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); headache (OR 0.84, 95% CI 0.56 to 1.27; 3 studies, 527 participants) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); abdominal pain (OR 0.93, 95% CI 0.61 to 1.41; 4 studies, 748 participants) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); constipation (OR 1.01, 95% CI 0.06 to 16.34; 1 study, 221 participants) (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>); fatigue (OR 0.66, 95% CI 0.39 to 1.09; 2 studies, 445 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); nasal congestion (OR 1.07, 95% CI 0.72 to 1.58; 2 studies, 445 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); haemoptysis (OR 0.65, 95% CI 0.33 to 1.28; 2 studies, 267 participants) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>); vomiting (OR 0.88, 95% CI 0.56 to 1.40; 4 studies, 748 participants) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); hearing impairment (OR 1.13, 95% CI 0.07 to 18.31; 1 study, 185 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>); tinnitus (OR 1.13, 95% CI 0.07 to 18.31; 1 study, 185 participants) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>); or rash (OR 0.20, 95% CI 0.01 to 4.30; 1 study, 82 participants) (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). We graded the certainty of evidence as moderate. Where there were data from four studies, the authors had planned to undertake a sensitivity analysis excluding any studies with a high risk of bias in any domain; however, none of the relevant studies had a high risk in any domain, so the authors did not conduct the planned sensitivity analysis. </p> <p>Investigators in the <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a> study narratively reported that no participants experienced temporary or permanent hearing loss in either group. Caparros‐Martin reported narratively that there were few adverse events and no difference between treatment groups (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). </p> </section> <section id="CD002203-sec-0068"> <p><b>b. Moderate</b></p> <p>We defined moderate adverse events as those which generally resulted in treatment being discontinued or which resulted in hospitalisation. In studies comparing azithromycin versus placebo, study withdrawals were rare and did not increase in the azithromycin group. <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a> reported that one participant receiving azithromycin discontinued treatment following an urticarial reaction. <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> reported that one participant in the azithromycin group developed ABPA and was withdrawn. </p> <p>Two studies reported serious adverse events that did not result in treatment being discontinued. In the <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a> study, four participants in the azithromycin group and three in the placebo group experienced a serious adverse event (OR 1.19, 95% CI 0.25 to 5.59; 1 study, 115 participants; <a href="./references#CD002203-fig-0011" title="">Analysis 1.6</a>) and <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a> reported one participant in the azithromycin group experienced an episode of distal intestinal obstructive syndrome (DIOS) (OR 3.05, 95% CI 0.12 to 75.81; 1 study, 221 participants; <a href="./references#CD002203-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD002203-sec-0069"> <p><b>c. Severe</b></p> <p>We defined severe adverse events as those which are life‐threatening or seriously debilitating. There were no severe adverse events reported in any of the included studies. </p> </section> </section> <section id="CD002203-sec-0070"> <h6 class="title">2. Number of days in hospital</h6> <p>Six studies reported on this outcome (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>;<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>) and we present the results in <a href="./references#CD002203-fig-0012" title="">Analysis 1.7</a>. </p> <p>There was no difference in the number of participants admitted to hospital at six weeks (OR 0.88, 95% CI 0.17 to 4.55; 1 study, 115 participants) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>). At six months, the earlier Saiman study (in adults and children) reported a reduced risk of hospitalisation with azithromycin, 29 out of 98 participants on placebo versus 14 out of 87 participants who received azithromycin (OR 0.46, 95% CI 0.22 to 0.94) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). This result was not mirrored in the second Saiman study (paediatric participants only) (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). When these data were combined, there was no difference between the azithromycin and placebo groups (OR 0.61, 95% CI 0.36 to 1.04; 2 studies, 445 participants; I<sup>2</sup> = 32%; high‐certainty evidence; <a href="./references#CD002203-fig-0012" title="">Analysis 1.7</a>). Similarly, there was no difference in the number of participants admitted to hospital in the <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a> study at 18 months (OR 0.96, 95% CI 0.51 to 1.81; 1 study, 221 participants; <a href="./references#CD002203-fig-0012" title="">Analysis 1.7</a>). </p> <p><a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a> did not demonstrate a reduction in the median (range) number of hospital inpatient days over three months (placebo: median 5.2 days (range 0 days to 36 days); azithromycin: median 2.1 days (range 0 days to 15 days) (P = 0.056)). </p> <p><a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a> reported the mean number of days in hospital for an exacerbation per year and found that participants in the azithromycin group had fewer days in hospital than the placebo group (MD ‐6.30 days, 95% CI ‐10.63 to ‐1.97; 1 study, 130 participants; <a href="./references#CD002203-fig-0013" title="">Analysis 1.8</a>). </p> </section> <section id="CD002203-sec-0071"> <h6 class="title">3. Acquisition or eradication of significant CF pathogens</h6> <section id="CD002203-sec-0072"> <p><b><i>a. P aeruginosa</i> </b></p> <p>Six studies reported on the acquisition of <i>P aeruginosa</i>, but the number of events was very low (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). We were only able to combine the data from the two Saiman studies at a single time point; overall, there was no difference between azithromycin and placebo (OR 0.64, 95% CI 0.28 to 1.49; 6 studies, 608 participants; <a href="./references#CD002203-fig-0014" title="">Analysis 1.9</a>). None of these studies had a high risk of bias in any domain, so we did not undertake the planned sensitivity analysis. </p> <p>In the Nichols study, participants were tested at baseline and then categorised based on their <i>P aeruginosa</i> status after six weeks. Of the 15 participants who were negative at baseline, one participant in the azithromycin group and one participant in the placebo group tested positive at six weeks (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>). There was no difference in acquisition of <i>P aeruginosa</i> between groups in the Saiman studies after six months (OR 0.64, 95% CI 0.21 to 2.00; 2 studies, 421 participants; moderate‐certainty evidence; <a href="./references#CD002203-fig-0014" title="">Analysis 1.9</a>) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). In the Clement study there was no new acquisition of <i>P aeruginosa</i> in either group after 12 months (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). </p> <p>The <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a> study reported on the number of participants with <i>P aeruginosa</i> recurrence after the first treatment quarter (56 days) and found no difference between groups (HR 1.00, 95% CI 0.64 to 1.55; 1 study, 200 participants) (result reported directly from the paper). </p> </section> <section id="CD002203-sec-0073"> <p><b>b. <i>S aureus</i> (including MRSA)</b></p> <p>Treatment with azithromycin was associated with a reduced risk of <i>S aureus</i> acquisition (OR 0.38, 95% CI 0.23 to 0.61; 6 studies, 552 participants; I<sup>2</sup> = 3%; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>) (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). This result includes different time points. The planned sensitivity analysis where authors excluded data from <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a> (the only study with a high risk of bias in any domain), showed no difference in the magnitude of effect. </p> <p>One study reported fewer events after two months (OR 0.05, 95% CI 0.00 to 0.99; 1 study, 31 participants; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>) (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>), whilst two studies reported the same effect after six months (OR 0.31, 95% CI 0.14 to 0.71; 2 studies, 240 participants; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>) (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). </p> <p><a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> reported that there was no difference in the acquisition of <i>S aureus</i> after 12 months (OR 0.19, 95% CI 0.02 to 1.70; 1 study, 82 participants; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>). Similarly, no difference in the acquisition of <i>S aureus</i> was seen after 18 months (OR 0.65, 95% CI 0.28 to 1.49; 1 study, 94 participants; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>) (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>), or 36 months (OR 0.43, 95% CI 0.14 to 1.28; 1 study, 105 participants; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>) (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). </p> <p>Two of these studies also looked at the number of participants with <i>S aureus</i> who had eradicated these bacteria at the end of the study (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). Treatment with azithromycin was not associated with increased eradication (OR 1.94, 95% CI 0.92 to 4.10; 2 studies, 220 participants; I² = 41%; <a href="./references#CD002203-fig-0016" title="">Analysis 1.11</a>). </p> <p>Saiman 2010 (n = 165) reported an increased risk of acquiring macrolide‐resistant <i>S aureus</i> for those participants on azithromycin (OR 5.01, 95% CI 2.14 to 11.71; <a href="./references#CD002203-fig-0017" title="">Analysis 1.12</a>). </p> <p>There was no evidence of increased risk of acquiring MRSA at any time point following treatment with azithromycin compared to placebo (OR 1.02, 95% CI 0.56 to 1.86; 5 studies, 755 participants; I² = 0%; <a href="./references#CD002203-fig-0018" title="">Analysis 1.13</a>). </p> </section> <section id="CD002203-sec-0074"> <p><b>c. <i>H influenzae</i> </b></p> <p>Four studies reported on the acquisition of <i>H influenzae</i> at different time points; at six months (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>), 12 months (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>), 18 months (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>), or 36 months (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). Combined data showed no difference between placebo and azithromycin (OR 0.97, 95% CI 0.57 to 1.64; 4 studies, 611 participants; I² = 0%; <a href="./references#CD002203-fig-0019" title="">Analysis 1.14</a>). None of these studies had a high risk of bias in any domain, so we did not undertake the planned sensitivity analysis. </p> <p>The second Saiman study (n = 240) reported acquisition of macrolide‐resistant <i>H influenzae</i> in 10 participants in the azithromycin group compared to one participant in the placebo group (OR 10.09, 95% CI 1.27 to 80.09; <a href="./references#CD002203-fig-0020" title="">Analysis 1.15</a>) (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). </p> </section> <section id="CD002203-sec-0075"> <p><b>d. Other significant pathogens</b></p> <p>There was no evidence of emergence of gram‐negative bacteria or other significant CF pathogens. Six studies reported that culture for non‐tuberculous mycobacterium (NTM) was undertaken on sputum samples and there was no evidence of emergence of this bacteria in participants treated with azithromycin (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Only two studies reported data that we could analyse (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>), with results showing no difference in recognised treatment‐emergent NTM (OR 0.35, 95% CI 0.06 to 1.95; 2 studies, 206 participants; I² = 0%; <a href="./references#CD002203-fig-0021" title="">Analysis 1.16</a>). In <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>, NTM was cultured on screening for one participant, who was subsequently discontinued from study drug (placebo) but included in the analysis. </p> </section> </section> <section id="CD002203-sec-0076"> <h6 class="title">4. Additional treatment required (courses or days of treatment)</h6> <section id="CD002203-sec-0077"> <p><b>a. Oral antibiotics</b></p> <p>Five studies reported the need for extra oral antibiotics (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). There was no difference between groups after six weeks (OR 0.51, 95% CI 0.18 to 1.42; 1 study, 115 participants; <a href="./references#CD002203-fig-0022" title="">Analysis 1.17</a>) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>). However, after six months treatment with azithromycin, fewer participants required additional oral antibiotics (OR 0.28, 95% CI 0.19 to 0.42; 3 studies, 527 participants; I² = 0%; <a href="./references#CD002203-fig-0022" title="">Analysis 1.17</a>) (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). Results from a single study showed no difference between groups after 18 months of azithromycin treatment (OR 0.71, 95% CI 0.40 to 1.25; 1 study, 221 participants; <a href="./references#CD002203-fig-0022" title="">Analysis 1.17</a>) (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). </p> <p><a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> (n = 82) reported the number of additional courses of oral antibiotics and the number of days of oral antibiotics. Investigators found that 12 months' treatment with azithromycin led to a reduction in both the number of courses (MD ‐1.70 courses, 95% CI ‐1.90 to ‐1.50; <a href="./references#CD002203-fig-0023" title="">Analysis 1.18</a>) and in the days of treatment (MD ‐12.00 days, 95% CI ‐17.63 to ‐6.37; <a href="./references#CD002203-fig-0024" title="">Analysis 1.19</a>). </p> </section> <section id="CD002203-sec-0078"> <p><b>b. Intravenous antibiotics</b></p> <p>Five studies reported the need for intravenous antibiotic treatment (<a href="./references#CD002203-fig-0025" title="">Analysis 1.20</a>) and did not demonstrate a difference between azithromycin or placebo at six weeks (OR 1.34 courses, 95% CI 0.22 to 8.37; 1 study, 115 participants) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>), at six months (OR 0.78 courses, 95% CI 0.49 to 1.23; 3 studies, 527 participants; I² = 9%; high‐certainty evidence) (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>), or at 18 months (OR 1.01 courses, 95% CI 0.53 to 1.94; 1 study, 221 participants) (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). </p> <p><a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> reported analysable data showing a reduction in both the mean number of courses of intravenous antibiotics (MD ‐0.80 courses, 95% CI ‐0.94 to ‐0.66; 1 study, 82 participants; <a href="./references#CD002203-fig-0026" title="">Analysis 1.21</a>) and the mean number of days of intravenous antibiotics (MD ‐12.00 days, 95% CI ‐13.96 to ‐10.04; 1 study, 82 participants; <a href="./references#CD002203-fig-0027" title="">Analysis 1.22</a>) over 12 months. </p> <p><a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a> reported fewer courses of intravenous antibiotic treatment with azithromycin (mean number of courses = 0.4, range zero to two courses) versus placebo (mean number of courses = 1.1, range zero to seven courses) (P &lt; 0.016). The same study also reported fewer days of intravenous antibiotic treatment with azithromycin (mean number of days = 2.0, range 0 to 14 days) versus placebo (mean number of days = 7.1, range 0 to 44 days) (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> </section> </section> <section id="CD002203-sec-0079"> <h6 class="title">5. Development of ABPA</h6> <p>The earlier Saiman study reported an increased incidence of wheeze in the azithromycin group, but no other evidence of ABPA (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). One participant treated with azithromycin in the <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> study was diagnosed with ABPA and withdrawn from the study (OR 0.34, 95% CI 0.01 to 8.63; 1 study, 82 participants; <a href="./references#CD002203-fig-0028" title="">Analysis 1.23</a>). </p> </section> <section id="CD002203-sec-0080"> <h6 class="title">6. Nutritional markers</h6> <section id="CD002203-sec-0081"> <p><b>BMI</b></p> <p>Overall, the reporting of nutritional parameters was limited. The <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> study measured the change in BMI z score after 12 months and found no difference between participants treated with azithromycin and placebo (MD 0.15, 95% CI ‐0.03 to 0.33; 1 study, 82 participants; <a href="./references#CD002203-fig-0029" title="">Analysis 1.24</a>). <a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a> calculated a mean BMI score at age three years (end of the study period); investigators reported no difference between azithromycin and placebo (MD 0.40, 95% CI ‐0.09 to 0.89; 1 study, 98 participants; <a href="./references#CD002203-fig-0030" title="">Analysis 1.25</a>). One study narratively reported no significant change in BMI (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> </section> <section id="CD002203-sec-0082"> <p><b>Weight</b></p> <p>Four studies measured the change in weight from baseline at different time points (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). After six weeks of azithromycin or placebo, <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a> found no difference between groups (MD 0.25 kg, 95% CI ‐0.29 to 0.79; 1 study, 108 participants; <a href="./references#CD002203-fig-0031" title="">Analysis 1.26</a>). After six months, both <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a> and <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a> reported a greater weight gain in participants receiving azithromycin (MD 0.62 kg, 95% CI 0.26 to 0.98; 2 studies, 445 participants; I² = 0%; <a href="./references#CD002203-fig-0031" title="">Analysis 1.26</a>). After 18 months of azithromycin, the <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a> study found little difference between groups for the change in weight (MD 1.27 kg, 95% CI 0.01 to 2.52; <a href="./references#CD002203-fig-0031" title="">Analysis 1.26</a>). </p> </section> </section> <section id="CD002203-sec-0083"> <h6 class="title">7. Liver disease</h6> <p>There were no reports of significant liver involvement from any study.</p> <p>Transient increases in liver transaminases were reported in some studies, but infrequently and with no increased risk for participants treated with azithromycin (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>). Three participants in the Caparros‐Martin study discontinued the study medication due to elevated liver enzyme concentrations (two in the azithromycin group and one in the placebo group) (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). </p> </section> <section id="CD002203-sec-0084"> <h6 class="title">8. QoL</h6> <p>Nine studies assessed QoL via a questionnaire (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Five studies used language‐appropriate versions of the CFQ or CFQ‐R (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>) or Cystic Fibrosis Respiratory Symptom Diary ‐ Chronic Respiratory Infection Symptom Score (CFRSD‐CRISS) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). These results are presented below. </p> <p>One study used the Chronic Respiratory Disease Questionnaire (which is not validated in CF) and narratively reported improvements in dyspnoea, emotional, mastery and total scores for all participants, but these were greater in the azithromycin group; also, improved fatigue scores were only seen in the azithromycin group (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). <a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a> used an unspecified QoL scale and reported no difference in QoL outcomes apart from the physical well‐being domain in which the azithromycin group scored better (MD 4.7 points, 95% CI 0.6 to 8.9). A third study reported on subjective well‐being and found no difference between groups (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>). </p> <section id="CD002203-sec-0085"> <p><b>CFQ‐R</b></p> <p><a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a> narratively reported no difference in any domain at 12 months; whilst <a href="./references#CD002203-bbs2-0008" title="O'ConnorBS , ReidAL , SteenHJ , ShieldsMD , ElbornJS . Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2008;7(Suppl 2):S25. [CFGD REGISTER: MA21] O'ConnorBS . The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa. Belfast, UK: Faculty of Medicine and Health Sciences, The Queen's University, 2009. ">O'Connor 2009</a> narratively reported an improvement in the vitality and physical functioning domains when comparing the azithromycin arm to the placebo arm of the cross‐over study. </p> <p>Overall score </p> <p>Only the earlier Saiman study reported on the change in total QoL score; at six months there was no difference between groups (MD 1.60, 95% CI ‐0.61 to 3.81; 1 study, 177 participants; moderate‐certainty evidence; <a href="./references#CD002203-fig-0032" title="">Analysis 1.27</a>). </p> <p>Physical domain </p> <p>After two months, <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a> found no difference in the physical domain of the CFQ‐R score (MD 8.40, 95% CI ‐8.25 to 25.05; 1 study, 28 participants; <a href="./references#CD002203-fig-0033" title="">Analysis 1.28</a>). After six months, <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a> found an improvement in this domain in the azithromycin group compared to a decrease in score in the placebo group (MD 2.70, 95% CI 0.09 to 5.31; <a href="./references#CD002203-fig-0033" title="">Analysis 1.28</a>). When these data were combined, there was a greater improvement with azithromycin compared to placebo (MD 2.84, 95% CI 0.26 to 5.42; 2 studies, 205 participants; <a href="./references#CD002203-fig-0033" title="">Analysis 1.28</a>). </p> <p>Respiratory symptoms domain </p> <p><a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a> reported a summary statistic showing no difference in overall CFQ‐R respiratory symptom score between groups after six weeks (MD 1.53 points, 95% CI ‐3.70 to 6.77. After two months, Steinkamp 2007 reported an improved respiratory symptom score in the azithromycin group compared to placebo (MD 15.40, 95% CI 2.16 to 28.64; 1 study, 26 participants; <a href="./references#CD002203-fig-0034" title="">Analysis 1.29</a>). </p> <p>Psychosocial domain </p> <p>Two studies reported on this domain, <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a> at two months and <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a> at six months. There was no difference in the psychosocial domain between azithromycin and placebo either individually or when data were combined (MD 0.08 (95% CI ‐3.14 to 3.30; 2 studies, 204 participants; <a href="./references#CD002203-fig-0035" title="">Analysis 1.30</a>)). </p> <p>Body image domain </p> <p>The same two studies reported on the body image domain (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). Again, there was no difference found, either individually or when data were combined (MD 2.73, 95% CI ‐0.54 to 6.01; 2 studies, 205 participants; <a href="./references#CD002203-fig-0036" title="">Analysis 1.31</a>). </p> <p>Eating disorder domain </p> <p>After two months, Steinkamp 2007 reported improvements in the azithromycin group compared to placebo for the eating disorder domain (MD 13.70, 95% CI 0.79 to 26.61; 1 study, 27 participants; <a href="./references#CD002203-fig-0037" title="">Analysis 1.32</a>). </p> <p>Problems with weight domain </p> <p>Similarly, after two months, Steinkamp 2007 found an improvement in the azithromycin group compared to a decrease in score in the placebo group for this domain (MD 35.20, 95% CI 14.82 to 55.58; 1 study, 26 participants; <a href="./references#CD002203-fig-0038" title="">Analysis 1.33</a>). </p> </section> <section id="CD002203-sec-0086"> <p><b>CFRSD‐CRISS</b></p> <p>Two studies assessed QoL using the CFRSD‐CRISS scale; neither found any difference between the azithromycin and the placebo groups after either six weeks using absolute change in points (MD −2.89 points, 95% CI −7.01 to 1.22; 1 study, 119 participants) (<a href="./references#CD002203-bbs2-0007" title="NCT02677701. Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH). https://clinicaltrials.gov/ct2/show/NCT02677701 Accessed 9 January 2023. [CFGD: PI323a]NicholsDP , BainesA , ChmielJF , NickJA , SaimanL , SinghP , et al. Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial. Pediatric Pulmonology2020;55 Suppl 2:150. [CFGD REGISTER: PI323b] NicholsDP , SinghPK , BainesA , CaverlyLJ , ChmielJF , GIbsonRL , et al. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax2022;77(6):581-8. [CFGD REGISTER: PI323c] ">Nichols 2020</a>) or after 18 months as a percentage change in score (MD ‐0.26%, 95% CI ‐6.38 to 5.85; 1 study, 221 participants) (<a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>). </p> </section> </section> <section id="CD002203-sec-0087"> <h6 class="title">10. Changes in inflammatory markers</h6> <section id="CD002203-sec-0088"> <p><b>a. BAL or sputum</b></p> <p>Two studies reported on levels of the inflammatory markers IL‐8 and neutrophil elastase (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>). <a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a> found lower levels with azithromycin of both IL‐8 (MD ‐1.20 pg/mL, 95% CI ‐1.88 to ‐0.52; 1 study, 103 participants; <a href="./references#CD002203-fig-0039" title="">Analysis 1.34</a>) and neutrophil elastase (MD ‐0.70 µg/mL, 95% CI ‐1.19 to ‐0.21; 1 study, 103 participants; <a href="./references#CD002203-fig-0040" title="">Analysis 1.35</a>) after 36 months. The Equi study found no difference in the median absolute difference between groups for either IL‐8 or neutrophil elastase (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>). </p> </section> <section id="CD002203-sec-0089"> <p><b>b. Blood</b></p> <p>One study reported that treatment with azithromycin had an effect on the time trend of the inflammatory marker C‐reactive protein (CRP) (P &lt; 0.001) over three months. Median values for CRP were stated to have fallen in the azithromycin group but to have remained stable in the placebo group (<a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). </p> <p>In a further study, participants were randomised following a two‐week course of IV antibiotics (<a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>). Over the eight‐week study period, CRP increased in both treatment arms; while this was not significantly more in the placebo group in our analysis (<a href="./references#CD002203-fig-0041" title="">Analysis 1.36</a>), this was reported as a significant difference in favour of azithromycin in the original published paper. </p> <p>The 12‐week Rotschild study examined antibodies against bactericidal or permeability‐increasing protein (BPI‐ANCA) and found no difference following treatment with placebo or azithromycin (<a href="./references#CD002203-bbs2-0010" title="RotschildM , EliasN , BerkowitzD , PollakS , ShinawiM , BeckR , et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clinical and Experimental Medicine2005;5(2):80-5. [CFGD REGISTER: MA18] ">Rotschild 2005</a>). </p> <p>The later Saiman study measured serum inflammatory markers at baseline, day 28 and day 168 of the study (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). Investigators reported small but significant reductions in serum myeloperoxidase, absolute neutrophil count and CRP in children treated with azithromycin at day 28, but not at day 168 (<a href="./references#CD002203-bbs2-0066" title="RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest 2012 May 17 [Epub ahead of print]. [DOI: 10.1378/chest.12-0628]">Ratjen 2012</a>). Due to the skewed distribution of the inflammatory markers, logarithmically transformed values were presented in the paper; for this reason, these data have not been included in this review. </p> </section> </section> </section> </section> <section id="CD002203-sec-0090"> <h4 class="title">High‐dose azithromycin compared to low‐dose azithromycin</h4> <p>We included one study with 47 participants (children aged five to 18) in this comparison of high‐dose oral azithromycin (15 mg/kg/day) with low‐dose oral azithromycin (5 mg/kg/day) (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). The treatment period was six months and investigators followed participants for 12 months. The results are summarised in <a href="./full#CD002203-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD002203-sec-0091"> <h5 class="title">Primary outcomes</h5> <section id="CD002203-sec-0092"> <h6 class="title">1. Lung function</h6> <section id="CD002203-sec-0093"> <p><b>a. FEV<sub>1</sub> </b></p> <p>The investigators reported within‐group differences for FEV<sub>1</sub>, stating there was no difference in mean FEV<sub>1</sub> % predicted between baseline and six months in either group. However, in the high‐dose group, there was a significant decline in FEV<sub>1</sub> % predicted from baseline at nine, 12 and 18 months (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). We graded the certainty of evidence as very low. </p> </section> <section id="CD002203-sec-0094"> <p><b>b. FVC</b></p> <p>FVC was stated as being comparable between groups at baseline and six months, but the data were not presented (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> <section id="CD002203-sec-0095"> <p><b>c. Non‐routine tests</b></p> <p>Similarly, FEF<sub>25-75</sub> and peak expiratory flow rate (PEFR) were also reported as being comparable between groups, but the data were not presented (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> </section> <section id="CD002203-sec-0096"> <h6 class="title">2. Respiratory exacerbations</h6> <p>There was no difference in the number of pulmonary exacerbations between the high‐dose and the low‐dose groups at six months (MD ‐0.05, 95% CI ‐0.20 to 0.10; <a href="./references#CD002203-fig-0042" title="">Analysis 2.1</a>) (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). We graded the certainty of evidence as very low. </p> </section> <section id="CD002203-sec-0097"> <h6 class="title">3. Survival</h6> <p>No deaths were reported (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> </section> <section id="CD002203-sec-0098"> <h5 class="title">Secondary outcomes</h5> <section id="CD002203-sec-0099"> <h6 class="title">3. Acquisition or eradication of significant CF pathogens</h6> <section id="CD002203-sec-0100"> <p><b>a. <i>P aeruginosa</i> </b></p> <p>The study reported that the number of children positive for <i>P aeruginosa</i> over the course of the study was similar between groups, but the investigators did not report how many cases were newly emergent (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> <section id="CD002203-sec-0101"> <p><b>b. <i>S aureus</i> (including MRSA)</b></p> <p>The distribution of <i>S aureus</i> was reported to be similar in the two groups (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> <section id="CD002203-sec-0102"> <p><b>d. Other significant pathogens</b></p> <p>The study also reported on <i>Streptococcus haemolyticus</i> , <i>Streptococcus pneumoniae</i> and <i>Candida albicans</i>; all organisms were reported to be similarly distributed in the two groups (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> </section> <section id="CD002203-sec-0103"> <h6 class="title">6. Nutritional markers</h6> <p>There was no difference in weight at either three months (MD 1.30 kg, 95% CI ‐7.12 to 9.72) or six months (MD ‐2.00 kg, 95% CI ‐10.75 to 6.75) (<a href="./references#CD002203-bbs2-0004" title="KabraSK , PawaiyaR , LodhaR , KapilA , KabraM , VaniAS , et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. Journal of Cystic Fibrosis2010;9(1):17-23. [CFGD REGISTER: MA25] ">Kabra 2010</a>). </p> </section> </section> </section> <section id="CD002203-sec-0104"> <h4 class="title">Nebulised azithromycin compared to oral azithromycin</h4> <p>One study (45 participants) compared nebulised azithromycin to oral azithromycin (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). The data for most of the outcomes were presented as baseline and endpoint values, but the SD for the change was not given. For this reason, we have not been able to analyse the data in this review, but reported the treatment effects directly from the paper, which does give the difference between the mean changes in each group. The results are summarised in <a href="./full#CD002203-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD002203-sec-0105"> <h5 class="title">Primary outcomes</h5> <section id="CD002203-sec-0106"> <h6 class="title">1. Lung function</h6> <section id="CD002203-sec-0107"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Mean change from baseline in FEV<sub>1</sub> % predicted was reported to be 5.89% (P &lt; 0.001) higher in the nebulised azithromycin group compared to the oral azithromycin group (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). We judged the certainty of evidence to be very low. </p> </section> </section> <section id="CD002203-sec-0108"> <h6 class="title">3. Survival</h6> <p>No deaths were reported.</p> </section> </section> <section id="CD002203-sec-0109"> <h5 class="title">Secondary outcomes</h5> <section id="CD002203-sec-0110"> <h6 class="title">1. Adverse effects</h6> <section id="CD002203-sec-0111"> <p><b>a. Mild</b></p> <p>Adverse events were reported narratively in the paper. The authors stated that there were no cases of intolerance following a test dose of azithromycin. Productive cough was reported more frequently in the nebulised azithromycin group; while diarrhoea, abdominal cramp, and heartburn were reported more frequently in the oral azithromycin group (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). We judged the certainty of evidence to be very low. </p> </section> </section> <section id="CD002203-sec-0112"> <h6 class="title">3. Acquisition or eradication of significant CF pathogens</h6> <section id="CD002203-sec-0113"> <p><b>a. <i>P aeruginosa</i> </b></p> <p>The mean change in <i>P aeruginosa</i> count was greater in the nebulised group and there was a greater decline in levels after 28 days (MD ‐0.5 log<sub>10</sub> CFU/g sputum (P &lt; 0.001)), which was described as significant (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). This result was statistically significant, but there is no recognised minimal clinically important difference (MCID) for the number of CFUs. We judged the certainty of evidence to be very low. </p> </section> </section> <section id="CD002203-sec-0114"> <h6 class="title">6. Nutritional markers</h6> <p>There was a greater increase in both weight (MD 0.56 kg, P = 0.001) and BMI (MD 0.23, P = 0.005) in the nebulised azithromycin group compared to the oral group (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). </p> </section> <section id="CD002203-sec-0115"> <h6 class="title">8. QoL</h6> <p>The study reported QoL using the PEDsQL‐4 scale and reported that QoL improved in both groups, but there was a greater mean improvement in the nebulised azithromycin group compared to the oral azithromycin group (MD ‐5.00, P &lt; 0.001) (<a href="./references#CD002203-bbs2-0005" title="IRCT2016100930233N1. Effect of nebulized azithromycin in cystic fibrosis disease. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2016100930233N1 (date first registered 30 Oct 2016). [CFGD REGISTER: MA33a] ManeshiA , ModaresiMR , KhaliliH , ShojaeL , FaghihiT . Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial. Iranian Journal of Pediatrics2019;29(6):e96977. [CFGD REGISTER: MA33b] [DOI: 10.5812/ijp.96977]">Maneshi 2019</a>). However, a higher score using the PEDsQL‐4 scale indicated a better QoL; the scores presented in Table 2 of the original paper showed that scores decreased from baseline in both the oral and nebulised groups, albeit the decrease was less with oral azithromycin. In our view, this does not constitute an improvement in QoL and the narrative description in the paper contradicts the data presented in the table. We judged the certainty of the evidence to be very low. </p> </section> </section> </section> <section id="CD002203-sec-0116"> <h4 class="title">Weekly azithromycin compared to daily azithromycin</h4> <p>One large Australian study with 208 participants compared daily versus weekly dosing regimens of azithromycin (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). The results are summarised in <a href="./full#CD002203-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD002203-sec-0117"> <h5 class="title">Primary outcomes</h5> <section id="CD002203-sec-0118"> <h6 class="title">1. Lung function</h6> <section id="CD002203-sec-0119"> <p><b>a. FEV<sub>1</sub> </b></p> <p>The relative change in FEV<sub>1</sub> % predicted was greater in the daily azithromycin group compared to the weekly dose at one month (MD ‐0.40% predicted, 95% CI ‐0.60 to ‐0.20; <a href="./references#CD002203-fig-0044" title="">Analysis 3.1</a>), at three months (MD ‐1.20% predicted, 95% CI ‐1.40 to ‐1.00; <a href="./references#CD002203-fig-0044" title="">Analysis 3.1</a>), and at six months (MD ‐0.70% predicted, 95% CI ‐0.95 to ‐0.45; moderate‐certainty evidence; <a href="./references#CD002203-fig-0044" title="">Analysis 3.1</a>) (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). Our analysis of the data favoured daily dosing at all reported time points; this disagrees with the paper which concluded that there was no difference between the two regimens, thus proving equivalence (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> <section id="CD002203-sec-0120"> <p><b>b. FVC</b></p> <p>Investigators stated that there was no difference between treatment groups at any time point for FVC, but did not present data (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> </section> <section id="CD002203-sec-0121"> <h6 class="title">2. Respiratory exacerbations</h6> <p>Our analysis showed a longer time until the first respiratory exacerbation in the weekly‐dose group (MD 17.30 days, 95% CI 4.32 days to 30.28 days; <a href="./references#CD002203-fig-0045" title="">Analysis 3.2</a>). However, these results were not consistent with the original authors' report, which suggested the difference was not significant (P = 0.17). The authors have been contacted for clarification, but we have not yet received a reply. </p> </section> <section id="CD002203-sec-0122"> <h6 class="title">3. Survival</h6> <p>No deaths were reported (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> </section> <section id="CD002203-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD002203-sec-0124"> <h6 class="title">1. Adverse effects</h6> <section id="CD002203-sec-0125"> <p><b>a. Mild</b></p> <p>Participants taking azithromycin weekly were more likely to have gastrointestinal adverse events (OR 3.62, 95% CI 1.61 to 8.14; Analysis 3.3), but there were no differences in total adverse effects (OR 1.58, 95% CI 0.85 to 2.91; moderate‐certainty evidence; Analysis 3.3) or abnormal liver transaminases (OR 0.24, 95% CI 0.85 to 2.91; Analysis 3.3) (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> <section id="CD002203-sec-0126"> <p><b>b. Moderate</b></p> <p>There was no difference in the number of participants who discontinued treatment (OR 2.53, 95% CI 0.86 to 7.46; <a href="./references#CD002203-fig-0046" title="">Analysis 3.3</a>) (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> </section> <section id="CD002203-sec-0127"> <h6 class="title">2. Number of days in hospital</h6> <p>The study did not demonstrate any difference between weekly and daily dosing with respect to the time spent in hospital (MD 0.00 days, 95% CI ‐2.97 to 2.97; <a href="./references#CD002203-fig-0047" title="">Analysis 3.4</a>) or the number of hospital admissions (MD 0.00 admissions, 95% CI ‐0.25 to 0.25; moderate‐certainty evidence; <a href="./references#CD002203-fig-0048" title="">Analysis 3.5</a>) (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> <section id="CD002203-sec-0128"> <h6 class="title">3. Acquisition or eradication of significant CF pathogens</h6> <section id="CD002203-sec-0129"> <p><b>a. <i>P aeruginosa</i> </b></p> <p>The study reported only that <i>P aeruginosa</i> was found in 66% of participants' sputum at baseline, that there was no difference between the weekly and daily groups, and that this percentage did not change over the course of the study (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> <section id="CD002203-sec-0130"> <p><b>b. <i>S aureus</i> (including MRSA)</b></p> <p><a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a> reported that a number of participants acquired azithromycin‐resistant <i>S aureus</i>,although there was no difference between groups (OR 0.65, 95% CI 0.11 to 3.96; <a href="./references#CD002203-fig-0049" title="">Analysis 3.6</a>). </p> </section> <section id="CD002203-sec-0131"> <p><b>c. <i>H influenzae</i> </b></p> <p>There were no isolates of <i>H influenzae</i> after six months (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> <section id="CD002203-sec-0132"> <p><b>d. Other significant pathogens</b></p> <p>After six months of treatment, there were no new isolates of <i>B cepacia</i> (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> </section> <section id="CD002203-sec-0133"> <h6 class="title">6. Nutritional markers</h6> <section id="CD002203-sec-0134"> <p><b>BMI</b></p> <p>There was no difference between groups in the change in BMI (adults) or BMI z scores (children) after six months of treatment (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> <section id="CD002203-sec-0135"> <p><b>Weight</b></p> <p>There was a slight difference favouring the daily group in weight z scores in participants aged less than 18 years (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> </section> <section id="CD002203-sec-0136"> <h6 class="title">8. QoL</h6> <section id="CD002203-sec-0137"> <p><b>CFQ</b></p> <p>There was an improvement in the physical domain of the CFQ in the weekly group (8.2 points, P = 0.02) and parents of children younger than 14 years reported higher scores for the health domain in the daily group. There were no differences in any other domain (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). We judged the certainty of evidence to be moderate for this outcome. </p> </section> </section> <section id="CD002203-sec-0138"> <h6 class="title">10. Changes in inflammatory markers</h6> <section id="CD002203-sec-0139"> <p><b>a. Blood</b></p> <p>The study demonstrated a greater fall in CRP (though not clinically relevant) in the daily compared to the weekly treatment group at one month (MD 2.10, 95% CI 1.70 to 2.50; <a href="./references#CD002203-fig-0050" title="">Analysis 3.7</a>), three months (MD 5.20, 95% CI 4.71 to 5.69; <a href="./references#CD002203-fig-0050" title="">Analysis 3.7</a>), and six months (MD 5.10, 95% CI 4.70 to 5.50; <a href="./references#CD002203-fig-0050" title="">Analysis 3.7</a>) (<a href="./references#CD002203-bbs2-0006" title="BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. 6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis. Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: MA20c] BellS , SerisierD , WainwrightC , BowlerS , SeniniS , WalmsleyK , et al. Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis. Respirology2006;11(Suppl 2):A11. [CFGD REGISTER: MA20b] McCormackJ , BellS , SeniniS , WalmsleyK , PatelK , WainwrightC , et al. Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal2007;30(3):487-95. [CFGD REGISTER: MA20a] SeniniS , McCormackJ . A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis. Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)2005. [CFGD REGISTER: MA20d] ">McCormack 2007</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002203-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002203-sec-0140"></div> <section id="CD002203-sec-0141"> <h3 class="title" id="CD002203-sec-0141">Summary of main results</h3> <p>We included 14 studies in this updated review with 1467 participants (both children and adults). Of these, two studies were of a cross‐over design and the remaining 12 were of a parallel design. All the studies looked at the effects of azithromycin: 11 compared oral azithromycin to matched placebo; one study compared high‐dose azithromycin (15 mg/kg/day) with low‐dose azithromycin (5 mg/kg/day) given orally; one study compared nebulised with oral azithromycin; and the final study compared a weekly oral dose of azithromycin to a daily dose. </p> <section id="CD002203-sec-0142"> <h4 class="title">Oral azithromycin compared to placebo</h4> <p>Azithromycin slightly improves FEV<sub>1</sub> % predicted compared to placebo at one, two and six months compared to placebo, although there was no difference seen at three months, four months or 12 months. Pulmonary exacerbations were recorded in different ways across the studies, but data reported at one, three, six and 12 months demonstrated that participants on azithromycin were more likely to be free of exacerbation. There was also moderate‐certainty evidence of a decreased risk of developing an exacerbation in the azithromycin group compared to the placebo group. </p> <p>Mild adverse events were common across the studies, but there was mostly no difference between groups. Adverse events more common in the azithromycin group included nausea and wheezing. Adverse events more common in the placebo group included cough and fever. There were no deaths or life‐threatening adverse events in any of the included studies. </p> <p>There was no difference in the number of hospital admissions at six months or in the acquisition of new <i>P aeruginosa</i> infection at 12 months or over. Neither was there a difference in the need for extra intravenous antibiotics or QoL score. </p> </section> <section id="CD002203-sec-0143"> <h4 class="title">High‐dose azithromycin (15 mg/kg/day) compared to low‐dose azithromycin (5 mg/kg/day)</h4> <p>The single study comparing a high dose of azithromycin to a low dose only included children. We are uncertain whether there is any difference between the two groups in either FEV<sub>1</sub> % predicted at six months or in the rate of exacerbations per child per month. The study did not report on any of our other clinically important outcomes: adverse events; hospitalisations; new acquisition of <i>P aeruginosa</i>; need for additional antibiotics; or QoL. </p> </section> <section id="CD002203-sec-0144"> <h4 class="title">Nebulised azithromycin compared to oral azithromycin</h4> <p>The single study for this comparison again only included children and we graded the certainty of the evidence across all outcomes to be very low. We were unable to include any data in our analyses and have reported findings directly from the paper. The authors reported that there was a greater mean change in FEV<sub>1</sub> % predicted at one month in the nebulised azithromycin group (P &lt; 0.001), but they did not report on excacerbations. In terms of adverse events, productive cough was reported more frequently in the nebulised azithromycin group whilst diarrhoea, abdominal cramp, and heartburn were reported more frequently in the oral azithromycin group; we judged the certainty of this evidence as very low. The authors also reported that there was a greater decline in <i>P aeruginosa</i> count in the nebulised treatment group (P &lt; 0.001) as well as a greater improvement in QoL score. The study did not report on hospitalisations or need for additional antibiotics. </p> </section> <section id="CD002203-sec-0145"> <h4 class="title">Weekly azithromycin compared to daily azithromycin</h4> <p>The single study included in this comparison provided moderate‐certainty evidence for weekly compared to daily azithromycin. There is probably a lower mean change in FEV<sub>1</sub> % predicted at six months in the weekly group compared to the daily group, but there is probably also a longer period of time until first exacerbation in the weekly group. There was no difference between groups in adverse events although gastrointestinal adverse events are probably more common in the weekly group. There was no difference between groups in the mean number of admissions to hospital or in QoL scores, except for the physical domain where there was probably a greater improvement in the weekly azithromycin group. The need for additional antibiotics was not reported and <i>P aeruginosa</i> was only reported as a frequency at baseline and did not report newly identified cases. </p> </section> </section> <section id="CD002203-sec-0146"> <h3 class="title" id="CD002203-sec-0146">Overall completeness and applicability of evidence</h3> <p>We are confident that we have identified all the studies that attempt to answer our review question; however, we have not been able to include studies of macrolide antibiotics other than azithromycin. We excluded studies looking at the effects of clarithromycin (<a href="./references#CD002203-bbs2-0018" title="BarkerPM , GillieDJ , SchechterMS , RubinBK . Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. American Journal of Respiratory and Critical Care Medicine2005;171(8):868-71. [CFGD REGISTER: MA23b] NCT00205634. Macrolide antibiotic therapy for patients with cystic fibrosis. www.clinicaltrials.gov/ct2/show/NCT00205634 (date first posted 20 Sep 2005). [CFGD REGISTER: MA23a] ">Barker 2005</a>; <a href="./references#CD002203-bbs2-0023" title="DogruD , DalgicF , KiperN , OzcelikU , YalcinE , AslanAT , et al. Effect of clarithromycin on inflammatory markers in bronchoalveolar lavage fluid in cystic fibrosis: a randomised, placebo-controlled crossover trial. Journal of Cystic Fibrosis2004;3(Suppl 1):S21. [CFGD REGISTER: MA22a] DoğruD , DalgiçF , KiperN , OzçelikU , YalçinE , AslanAT , et al. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turkish Journal of Pediatrics2009;51(5):416-23. [CFGD REGISTER: MA22b] ">Dogru 2004</a>; <a href="./references#CD002203-bbs2-0025" title="FrederiksenB , KochC , HoibyN , PresslerT . Clinical efficacy of clarithromycin in CF patients with chronic lung infection. In: Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna. 2001:P208. [CFGD REGISTER: MA4] ">Frederiksen 2001</a>; <a href="./references#CD002203-bbs2-0028" title="KessarisA , SouliM , InglezosI , KanellakopoulouK , ApostolopoulouF , GiamarellouE . Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization. The European Respiratory Journal2003;22 Suppl 45:514s. [CFGD REGISTER: MA13] ">Kessaris 2003</a>; <a href="./references#CD002203-bbs2-0030" title="OrdonezCL , StulbargM , GrundlandH , LiuJT , BousheyHA . Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatric Pulmonology2001;32(1):29-37. [CFGD REGISTER: MA7] ">Ordonez 2001</a>; <a href="./references#CD002203-bbs2-0032" title="PukhalskyAL , ShmarinaGV , KapranovNI , KokarovtsevaSN , Kashirskaja NJu, LubskayaTV . Immunoregulatory effect of a 14-membered ring macrolide antibiotic in cystic fibrosis patients. European Respiratory Journal2001;18(Suppl 33):126s. [CFGD REGISTER: IB44d] PukhalskyAL , ShmarinaGV , KapranovNI , KokarovtsevaSN , PukhalskayaD , KashirskajaNJ . Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators of inflammation2004;13(2):111-7. [CFGD REGISTER: IB44c] PukhalskyAL , ShmarinaGV , KaproanovNI , KashirskajaNJ , KokarovtsevaSN , Shabalova LA et al. Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis. Pediatric Pulmonology2001;32 Suppl 22:274. [CFGD REGISTER: IB44b] ShmarinaGV , PukhalskyAL , KashirskajaNJ , Research Centre for Medical Genetics MR. Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic). European Respiratory Journal2004;24(Suppl 48):P3758. [CFGD REGISTER: IB44a] ">Pukhalsky 2001</a>; <a href="./references#CD002203-bbs2-0034" title="SriramS , YoungJ , WaterhouseJC , BucknallCE , StackBH . The antinflammatory effect of clarithromycin in CF. Journal of Cystic Fibrosis2003;2 (Suppl 1):S52. [CFGD REGISTER: MA10] ">Sriram 2003</a>) and roxithromycin (<a href="./references#CD002203-bbs2-0022" title="DionyssopoulouV , PerpatiG , StefanatouE , ChristodoulouE , KalatziE , ArmeniakouE , et al. Laboratory and clinical effect of long-term roxithromycin treatment in adult patients with cystic fibrosis [abstract]. Journal of Cystic Fibrosis2005;4(Suppl 1):S24. [CFGD REGISTER: MA15] ">Dionyssopoulou 2005</a>), due to a lack of information or inappropriate study design. These studies were over 15 years old with no studies carried out more recently. </p> <p>The combined data from the azithromycin studies can provide us with confidence concerning the impact on respiratory function and other more pragmatic outcomes, such as the need for oral antibiotics and risk of respiratory exacerbation. The studies enroled a broad range of participants over the age of six years, with and without chronic <i>P aeruginosa</i> airway infection. To date, 1467 children and adults have been enroled in RCTs evaluating azithromycin for treating people with CF. In previous versions of this review, we were not able to include any studies of children younger than six years of age. In this update, we have included two studies with younger children (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>; <a href="./references#CD002203-bbs2-0009" title="MagaretAS , SalernoJ , DeenJF , KlosterM , Mayer-HamblettN , RamseyBW , et al. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis2021;20(2):e16-8. [CFGD REGISTER: MA31f] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177-87. [CFGD REGISTER: MA31b] Mayer-HamblettN , Retsch-BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CFGD REGISTER: MA31d] MontuschiP , LucidiV , ParisD , MontemitroE , ShohrehR , MoresN , et al. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis. Frontiers in Pharmacology2018;9:595. [CFGD REGISTER: MA31e] [DOI: 10.3389/fphar.2018.00595]NCT02054156. Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis. clinicaltrials.gov/show/NCT02054156 (date first posted 04 Feb 2014). [CFGD REGISTER: MA31c] RamseyBW , Retsch-BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52(Suppl 47):380-1. [ABSTRACT NO.: 434] [CFGD REGISTER: MA31a] ">OPTIMIZE 2018</a>), giving a more complete picture of the effectiveness of macrolide antibiotics. This is particularly pertinent following the expansion of newborn screening for CF and the discrepancy in the advice regarding the need for long‐term antibiotic prophylaxis in these infants (<a href="./references#CD002203-bbs2-0069" title="RosenfeldM , RaynerO , SmythAR . Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews2020, Issue 9. Art. No: CD001912. [DOI: 10.1002/14651858.CD001912.pub5]">Rosenfeld 2020</a>). </p> <p>A potentially confounding variable to be considered is chronic infection of the airways with <i>P aeruginosa</i> . One study enroled people with CF and chronic <i>P aeruginosa</i> infection (<a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>) and one study without (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>); other studies have enroled both populations. While the later Saiman study did not demonstrate a significant improvement in the primary outcome of relative change in FEV<sub>1</sub>, when these data were included in our meta‐analysis, they did not change the overall result after six months and were consistent with other study results (<a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a>). In the Clement study, subgroup analysis of participants with and without chronic <i>P aeruginosa</i> infection did not alter the overall results, although data at six months were not presented (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>). </p> <p>In terms of outcomes, only one study did not report on our primary outcome of change in FEV<sub>1</sub> (<a href="./references#CD002203-bbs2-0002" title="ACTRN12610001072000. Prevention of bronchiectasis in infants with cystic fibrosis. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610001072000 (first registered 6 Dec 2010). [CFGD REGISTER: MA29e] Caparros-MartinJ , SaladieM , Agudelo-RomeroP , WareR , SlyP , StickS , et al. Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S231. [CFGD REGISTER: MA29a] FotiA , WareR , TiddensH , SlyP , StickS . Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 2:S274. [CFGD REGISTER: MA29b] NCT01270074. Prevention of Bronchiectasis in Infants With Cystic Fibrosis. www.clinicaltrials.gov2011. [CFGD: MA29d] StickSM , FotiA , WareRS , TiddensHA , ClementsBS , ArmstrongDS , et al. The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine2022;10(8):776-84. [CFGD REGISTER: MA29c] ">COMBAT CF 2022</a>). This study included infants from birth to 36 months of age and spirometry in this age group would be inappropriate. Only nine of our studies reported on exacerbations and they measured exacerbations in various different ways (number with an exacerbation, exacerbation rate, time to first exacerbation etc.), making it difficult to combine data. Similarly, with adverse events, these were categorised and reported in different ways, making synthesis difficult. </p> <p>None of our included studies reported on liver disease and whilst QoL was measured in most of the studies, none reported specifically on treatment burden. </p> <p>Overall, there is no sufficient evidence to advocate azithromycin therapy in any particular subgroup of people with CF (for example, children over six years of age or those with chronic <i>P aeruginosa</i> airway infection). </p> </section> <section id="CD002203-sec-0147"> <h3 class="title" id="CD002203-sec-0147">Quality of the evidence</h3> <p>We have presented the certainty of evidence by outcome for each of the comparisons included in the review in the summary of findings tables (<a href="./full#CD002203-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD002203-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002203-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002203-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD002203-sec-0148"> <h4 class="title">Oral azithromycin compared to placebo</h4> <p>We included 11 studies in this comparison, although we were not able to combine data from all the studies. Despite this, we graded the certainty of evidence as moderate to high. There was little risk of bias in the design of the studies and there were sufficient numbers of participants to be applicable to the more general CF population for our primary outcomes. We downgraded the certainty of evidence for pulmonary exacerbations and new acquisition of <i>P aeruginosa</i> because the studies contributing data were conducted in a paediatric population and the findings may not apply to an adult population. We also downgraded the certainty of evidence for adverse events due to heterogeneity in the way that these were measured and reported. We downgraded the certainty of evidence for QoL measurement as there was only one study reporting this outcome which reduced the number of participants contributing data (<a href="./full#CD002203-tbl-0001">summary of findings Table 1</a>). We undertook sensitivity analyses on two of our analyses, where we combined data from at least four studies and excluded any study which had a high risk of bias in any domain assessed (<a href="./references#CD002203-fig-0006" title="">Analysis 1.1</a>; <a href="./references#CD002203-fig-0015" title="">Analysis 1.10</a>). We excluded <a href="./references#CD002203-bbs2-0013" title="SteinkampG , Schmitt-GroheS , DoringG , StaabD , PfrunderD , BeckG , et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respiratory Medicine2008;102(11):1643-53. [CFGD REGISTER: MA19c] SteinkampG , Schmitt-GroheS , DoringG , StabbD , SchubertR , ZielenS . Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection. Pediatric Pulmonology2007;42(Suppl 30):300. [CFGD REGISTER: MA19b] SteinkampG , Schmitt-GroheS , DoringG , WorlitzschD , StaabD , SchubertR , et al. Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]. Journal of Cystic Fibrosis2006;5(Suppl):S25. [CFGD REGISTER: MA19a] ">Steinkamp 2007</a>, which had a high risk of other potential bias, but in both analyses the magnitude of the treatment effect remained the same. </p> </section> <section id="CD002203-sec-0149"> <h4 class="title">High‐dose azithromycin compared to low‐dose azithromycin</h4> <p>We were only able to include one study for this comparison; the study reported data for only two of our outcomes (FEV<sub>1</sub> % predicted and pulmonary exacerbations). We judged that the certainty of evidence for this comparison was very low due to risk of bias within the single study, imprecision due to low participant numbers, and indirectness as the study only included children (<a href="./full#CD002203-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD002203-sec-0150"> <h4 class="title">Nebulised azithromycin compared to oral azithromycin</h4> <p>The certainty of evidence for this comparison was very low due to: firstly, the risk of bias within the single included study, particularly across the domains of randomisation, blinding and completeness of data; imprecision due to low participant numbers; and indirectness as the results were only applicable to a paediatric population. </p> </section> <section id="CD002203-sec-0151"> <h4 class="title">Weekly azithromycin compared to daily azithromycin</h4> <p>We judged the certainty of evidence for this comparison to be moderate despite there only being one included study. We downgraded the evidence only for imprecision due to low participant numbers. </p> </section> </section> <section id="CD002203-sec-0152"> <h3 class="title" id="CD002203-sec-0152">Potential biases in the review process</h3> <p>We are confident that all eligible studies have been identified, and we contacted authors for additional information where necessary. </p> <p>Two new authors (SS, DK) joined the author team for this update and carried out the searches, screening and data extraction. However, previously included studies were reviewed when adding the new data and there was liaison with the authors of the previous review versions. </p> <p>In this update, we have split the review into four comparisons as we felt that the results were more reflective of practice than when different variations of macrolide therapy were combined. </p> </section> <section id="CD002203-sec-0153"> <h3 class="title" id="CD002203-sec-0153">Agreements and disagreements with other studies or reviews</h3> <p>A previous meta‐analysis by Florescu evaluated azithromycin for people with CF (<a href="./references#CD002203-bbs2-0052" title="FlorescuDF , MurphyPJ , KalilAC . Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulmonary Pharmacology and Therapeutics2009;22(6):467-72.">Florescu 2009</a>) and included data from four studies also included in this review (<a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; <a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>; <a href="./references#CD002203-bbs2-0011" title="MaginAF , SpieglerP . The benefits of azithromycin are not related to its antibacterial action. Clinical Pulmonary Medicine2004;11(1):60-1. [CFGD REGISTER: MA11f] NguyenD , EmondMJ , Mayer-HamblettN , SaimanL , MarshallBC , BurnsJL . Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatric Pulmonology2007;42(6):533-41. [CFGD REGISTER: MA11e] NguyenD , Mayor-HamblettN , MarshallBC , SaimanL , BurnsJL . Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients. Pediatric Pulmonology2004;38(Suppl 27):286. [CFGD REGISTER: MA11c] SaimanL , MarshallBC , Mayer-HamblettN , BurnsJL , QuittnerAL , CibeneDA , et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2003;290(13):1749-56. [CFGD REGISTER: MA11a] SaimanL , Mayer-HamblettN , CampbellP , MarshallBC . Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2005;172(8):1008-12. [CFGD REGISTER: MA11d] SaimanL . What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial. Pediatric Pulmonology2003;36 Suppl 25:165-7. [CFGD REGISTER: MA11b] ">Saiman 2003</a>; <a href="./references#CD002203-bbs2-0014" title="BellSC , SeeneyS , WalmsleyK , WolterJM , BowlerSD , McCormackJG . Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis. Pediatric Pulmonology2002;34 Suppl 24:289-90. [CFGD REGISTER: MA3c] BowlerSD , MaselPJ , BellSC , SeeneySL , WolterJM , McCormackJG . A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]. Pediatric Pulmonology2000;30 Suppl 20:280. [CFGD REGISTER: MA3a] BowlerSD , SeeneyS , WalmsleyK , WolterJM , BellSC , McCormackJG . Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis. Respirology2002;7 Suppl 1:A9. [CFGD REGISTER: MA3e] BowlerSD . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis. Japanese Journal of Antibiotics2003;56(Suppl A):38. [CFGD REGISTER: MA3f] SeeneySL , BowlerSD , WolterJM , BellSC , MaselPJ , McCormackJG . A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes. Internal Medicine Journal2001;31 Suppl:A12. [CFGD REGISTER: MA3d] WolterJ , SeeneyS , BellS , BowlerS , MaselP , McCormackJ . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57(3):212-6. [CFGD REGISTER: MA3b] WolterJM , SeeneySL , BowlerSD , MaselPJ , BellSC , McCormackJG . Azithromycin (AZM) in adults with cystic fibrosis. Respirology2001;6 Suppl:A38. [CFGD REGISTER: MA3g] ">Wolter 2002</a>). Only data from the first arm of the Equi cross‐over study were included (<a href="./references#CD002203-bbs2-0003" title="EquiA , Balfour-LynnIM , BushA , RosenthalM . Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360(9338):978-84. [CFGD REGISTER: MA6b] EquiA , BushA , AltonEW , Balfour-LynnI , RosenthalM . A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]. Pediatric Pulmonology2001;Suppl 22:307. [CFGD REGISTER: MA6a] EquiA , BushA , Balfour-LynnIM . A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis. Thorax2002;Suppl 3:iii38. [CFGD REGISTER: MA6c] ">Equi 2002</a>). The authors demonstrated a significant increase in FEV<sub>1</sub> with azithromycin compared to placebo (MD 3.53%, 95% CI 0.0 to 7.1%; P = 0.05) and reported significant heterogeneity, which reduced when data from participants chronically infected with <i>P aeruginosa</i> were analysed separately. Whilst we have demonstrated a similar small but significant improvement in the relative change in FEV<sub>1</sub>, we do not agree with the conclusion that heterogeneity relates to <i>P aeruginosa</i> infection. The reasons for this are: </p> <p> <ol id="CD002203-list-0012"> <li> <p>We have included data from all time points reported in <a href="./references#CD002203-bbs2-0001" title="ClementA , TamaletA , Le RouxE , RavillyS , FaurouxB , JaisJP . Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax2006;61(10):895-902. [CFGD REGISTER: MA14c] ClementA , TamaletA , Le RouxE , RavillyS , JaisJP . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial. Journal of Cystic Fibrosis2005;4(Suppl 1):S68. [CFGD REGISTER: MA14a] ClementA , TamaletA , LerouxE , RavillyS , JaisJ . Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial. Pediatric Pulmonology2005;40(Suppl 28):285. [CFGD REGISTER: MA14b] ">Clement 2006</a>; </p> </li> <li> <p>We do not feel it is appropriate to combine data from 6 and 12 months (we have reported data from each time point separately); and </p> </li> <li> <p>We have included data from the <a href="./references#CD002203-bbs2-0012" title="AnsteadM , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):377, Abstract no: 440. [CFGD REGISTER: MA24f] DongK , SinghA , NgRT , SinDD , TebbuttSJ , RatjenF , et al. Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis. Chest2019;156(4):667-73. [CFGD REGISTER: MA24m] FitzsimmonsLF , SmithKP , KlosterM , BurnsJL , WargoMJ . Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung. Pediatric Pulmonology2013;48:309. [CFGD REGISTER: MA24L] GreenN , BurnsJL , Mayer-HamblettN , KlosterM , LandsLC , AnsteadM , RatjenF , SaimanL . Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis. Journal of Clinical Microbiology2011;49(7):2772-3. [CFGD REGISTER: MA24k] HamblettNM , SaimanL , KlosterM , AnsteadM , LandsLC , FischerL , et al. Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial. Pediatric Pulmonology2012;47 Suppl 35:292. [ABSTRACT NO.: 199] [CFGD REGISTER: MA24i] Mayer-HamblettN , SaimanL , LandsLC , AnsteadM , RosenfeldM , KlosterM , et al. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials2013;36(1):99-105. [CFGD REGISTER: MA24j] NCT00431964. Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa. https://clinicaltrials.gov/show/NCT004319642007. [CFGD: MA24b]RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , EmmettP , et al. The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2010;45(Suppl 33):271, Abstract no:149. [CFGD REGISTER: MA24e] RatjenF , SaimanL , Mayer-HamblettN , LandsLC , KlosterM , ThompsonV , et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa . Chest2012;142(5):1259-66. [CFGD REGISTER: MA24g] [DOI: 10.1378/chest.12-0628]SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA2010;303(17):1707-15. [CFGD REGISTER: MA24c] SaimanL , AnsteadM , Mayer-HamblettN , LandsLC , KlosterM , Hocevar-TrnkaJ , et al. Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]. JAMA2010;303(17):1707-15 Online. [CFGD REGISTER: MA24d] SaimanL , AnsteadM , RatjenF , LandsL . Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa . www.clinicaltrials.gov (accessed 04 March 2010)2007. [CFGD REGISTER: MA24b] SaimanL , Mayer-HamblettN , AnsteadM , LandsLC , KlosterM , GossCH , et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology2012 ;47(7):641-8. [CFGD REGISTER: MA24h] SaimanL . Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]. Pediatric Pulmonology2009;44(32):185. [CFGD REGISTER: MA24a] ">Saiman 2010</a> study (and other smaller studies). </p> </li> </ol> </p> <p>With these factors, our data were more homogeneous and the impact of chronic <i>P aeruginosa</i> infection was not apparent. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002203-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD002203-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD002203-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD002203-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV1 (% predicted)" data-id="CD002203-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV1 (% predicted)" data-id="CD002203-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 1: FEV1 % predicted (mean change from baseline)" data-id="CD002203-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 1: FEV<sub>1</sub> % predicted (mean change from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 2: FVC % predicted (percentage change from baseline)" data-id="CD002203-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 2: FVC % predicted (percentage change from baseline) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 3: Number free of pulmonary exacerbation" data-id="CD002203-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 3: Number free of pulmonary exacerbation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 4: Time to first pulmonary exacerbation" data-id="CD002203-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 4: Time to first pulmonary exacerbation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 5: Adverse effects of antibiotic treatment" data-id="CD002203-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 5: Adverse effects of antibiotic treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 6: Serious adverse events" data-id="CD002203-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 6: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 7: Admission to hospital" data-id="CD002203-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 7: Admission to hospital</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 8: Number of days in hospital" data-id="CD002203-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 8: Number of days in hospital</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 9: Acquisition of Pseudomonas aeruginosa" data-id="CD002203-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 9: Acquisition of <i>Pseudomonas aeruginosa</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 10: Acquisition of Staphylococcal aureus" data-id="CD002203-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 10: Acquisition of <i>Staphylococcal aureus</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 11: Eradication of Staphylococcal aureus present at baseline" data-id="CD002203-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 11: Eradication of <i>Staphylococcal aureus</i> present at baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 12: Acquisition of macrolide‐resistant Staphylococcal aureus" data-id="CD002203-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 12: Acquisition of macrolide‐resistant <i>Staphylococcal aureus</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 13: Acquisition of meticillin‐resistant Staphylococcus aureus (MRSA)" data-id="CD002203-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 13: Acquisition of meticillin‐resistant <i>Staphylococcus aureus</i> (MRSA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 14: Acquisition of Haemophilus influenzae" data-id="CD002203-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 14: Acquisition of <i>Haemophilus influenzae</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 15: Acquisition of macrolide‐resistant Haemophilus influenzae" data-id="CD002203-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 15: Acquisition of macrolide‐resistant <i>Haemophilus influenzae</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 16: Acquisition of non‐tuberculous mycobacterium" data-id="CD002203-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 16: Acquisition of non‐tuberculous mycobacterium </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 17: Need for additional oral antibiotics" data-id="CD002203-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 17: Need for additional oral antibiotics</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 18: Number of courses of oral antibiotics" data-id="CD002203-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 18: Number of courses of oral antibiotics</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 19: Number of days of additional oral antibiotics" data-id="CD002203-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 19: Number of days of additional oral antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 20: Need for intravenous antibiotics" data-id="CD002203-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 20: Need for intravenous antibiotics</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 21: Number of courses of intravenous antibiotics" data-id="CD002203-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 21: Number of courses of intravenous antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 22: Number of days of intravenous antibiotics" data-id="CD002203-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 22: Number of days of intravenous antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 23: Development of allergic bronchopulmonary aspergillosis" data-id="CD002203-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 23: Development of allergic bronchopulmonary aspergillosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 24: Change in BMI z score" data-id="CD002203-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 24: Change in BMI z score</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 25: Mean BMI score at 3 years of age" data-id="CD002203-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 25: Mean BMI score at 3 years of age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 26: Change in weight (kg) from baseline" data-id="CD002203-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 26: Change in weight (kg) from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 27: Change in total quality of life score (CFQ‐R)" data-id="CD002203-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 27: Change in total quality of life score (CFQ‐R) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 28: Change in physical domain of CFQ‐R QoL score" data-id="CD002203-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 28: Change in physical domain of CFQ‐R QoL score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 29: Change in respiratory symptom domain of CFQ‐R QoL score" data-id="CD002203-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 29: Change in respiratory symptom domain of CFQ‐R QoL score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 30: Change in psychosocial domain of CFQ‐R QoL score" data-id="CD002203-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 30: Change in psychosocial domain of CFQ‐R QoL score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 31: Change in body image domain of CFQ‐R QoL score" data-id="CD002203-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 31: Change in body image domain of CFQ‐R QoL score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 32: Change in eating disorder domain of CFQ‐R QoL score" data-id="CD002203-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 32: Change in eating disorder domain of CFQ‐R QoL score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 33: Change in problems with body weight domain of the CFQ‐R QoL score" data-id="CD002203-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 33: Change in problems with body weight domain of the CFQ‐R QoL score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 34: Change in inflammatory markers: IL‐8 pg/mL" data-id="CD002203-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 34: Change in inflammatory markers: IL‐8 pg/mL </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 35: Change in inflammatory markers: neutrophil elastase µg/mL" data-id="CD002203-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 35: Change in inflammatory markers: neutrophil elastase µg/mL </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-001.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin versus placebo, Outcome 36: Change in CRP" data-id="CD002203-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-001.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin versus placebo, Outcome 36: Change in CRP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-001.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose azithromycin compared to low dose azithromycin, Outcome 1: Pulmonary exacerbation rate (per child, per month)" data-id="CD002203-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: High dose azithromycin compared to low dose azithromycin, Outcome 1: Pulmonary exacerbation rate (per child, per month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: High dose azithromycin compared to low dose azithromycin, Outcome 2: Weight (kg) absolute values" data-id="CD002203-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: High dose azithromycin compared to low dose azithromycin, Outcome 2: Weight (kg) absolute values </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 1: Relative change in FEV1 (% predicted)" data-id="CD002203-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 1: Relative change in FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 2: Days to first pulmonary exacerbation" data-id="CD002203-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 2: Days to first pulmonary exacerbation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 3: Adverse events" data-id="CD002203-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 3: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 4: Days in hospital" data-id="CD002203-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 4: Days in hospital</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 5: Number of hospital admissions" data-id="CD002203-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 5: Number of hospital admissions</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 6: Acquisition of azithromycin‐resistant Staphylococcal aureus" data-id="CD002203-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 6: Acquisition of azithromycin‐resistant <i>Staphylococcal aureus</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002203-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/urn:x-wiley:14651858:media:CD002203:CD002203-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Weekly versus daily azithromycin, Outcome 7: Change in CRP" data-id="CD002203-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_t/tCD002203-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Weekly versus daily azithromycin, Outcome 7: Change in CRP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/media/CDSR/CD002203/image_n/nCD002203-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002203-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ oral azithromycin compared to placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral azithromycin versus placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> oral azithromycin </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty</b> </p> <p><b>of the</b> </p> <p><b>evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted: mean change from baseline</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted </p> <p>ranged across control groups</p> <p>from ‐3.00% to 3.45%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention groups was </p> <p>3.97% higher</p> <p>(1.74 higher to 6.19 higher).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>549</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was also reported at other time points.</p> <p>At one month </p> <p>MD 3.99 % (95% CI 1.47 to 6.51); 2 studies, 229 participants</p> <p>At two months </p> <p>MD 2.37 % (95% CI 0.33 to 4.41); 5 studies, 310 participants</p> <p>At three months </p> <p>MD 2.70 % (95% CI ‐0.12 to 5.52); 2 studies, 225 participants</p> <p>At four months </p> <p>MD 5.19 % (95% CI ‐0.31 to 10.68); 2 studies, 123 participants</p> <p>At 12 months </p> <p>MD ‐0.13 (95% CI ‐4.96 to 4.70); 2 studies, 152 participants</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: time</b> </p> <p><b>to next exacerbation</b> </p> <p><b>Follow‐up: 6 to 36 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a longer time to exacerbation in the azithromycin group compared to the placebo group, HR 0.61 (95% CI 0.50 to 0.75). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>796</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The majority of participants in the included studies were 18 years or younger. Only 1 of the 4 studies included adults. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events: number of mild</b> </p> <p><b>treatment‐related</b> </p> <p><b>adverse events</b> </p> <p><b>Follow‐up: 6 to 18 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mild adverse events were common across the studies.</p> <p>There was no difference between groups in the reporting of diarrhoea, OR 1.43 (95% CI 0.81 to 2.50; 4 studies, 748 participants); sore throat, OR 0.85 (95% CI 0.57 to 1.26; 2 studies, 445 participants); rhinorrhoea, OR 0.91 (95% CI 0.59 to 1.38; 2 studies, 445 participants); headache, OR 0.84 (95% CI 0.56 to 1.27; 3 studies, 527 participants); abdominal pain, OR 0.93 (95% CI 0.61 to 1.41; 4 studies, 748 participants); constipation, OR 1.01 (95% CI 0.06 to 16.34; 1 study, 221 participants); fatigue, OR 0.66 (95% CI 0.39 to 1.09; 2 studies, 445 participants); nasal congestion, OR 1.07 (95% CI 0.72 to 1.58; 2 studies, 445 participants); vomiting, OR 0.88 (95% CI 0.56 to 1.40; 4 studies, 748 participants); hearing impairment, OR 1.13 (95% CI 0.07 to 18.31; 1 study, 185 participants); or tinnitus, OR 1.13 (95% CI 0.07 to 18.31; 1 study, 185 participants). </p> <p>Adverse events more common in the azithromycin group included nausea, OR 1.69 (95% CI 0.99 to 2.87; 2 studies, 445 participants); and wheezing, OR 2.13 (95% CI 1.07 to 4.25; 2 studies, 445 participants). </p> <p>Adverse events less common in the azithromycin group included cough, OR 0.46 (95% CI 0.30 to 0.69; 2 studies, 445 participants); and fever, OR 0.65 (95% CI 0.43 to 0.97; 3 studies, 527 participants). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748</p> <p>(4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no severe adverse events reported in any of the studies and moderate adverse events (resulting in discontinuation of the treatment) only occurred in 2 studies (1 participant in each). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations: admissions to hospital</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> <p>(76 to 191)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.61 (0.36 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported at 6 weeks and found no difference in hospital admissions, OR 0.88 (95% CI 0.17 to 4.55). </p> <p>A second study reported on hospital admissions at 18 months but found no difference between groups, OR 0.96 (95% CI 0.51 to 1.81). </p> <p>A further study reported the number of days in hospital and found that participants in the azithromycin group had fewer days in hospital than the placebo group (MD ‐6.30 days, 95% CI ‐10.63 to ‐1.97; 1 study, 130 participants). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA</b> </p> <p><b>Follow‐up: 12 months and over</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference in new acquisition of PA at 12 months and no difference in recurrence after first treatment quarter, HR 1.00 (95% CI 0.64 to 1.55). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At other time points, there were no differences between groups in new acquisition of PA, but numbers were low. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics: participants needing extra IV antibiotics</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> <p>(110 to 237)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.78 (0.49 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies also reported on the need for extra oral antibiotics and found that after 6 months there was a lower risk of needing extra antibiotics, OR 0.28 (95% CI 0.19 to 0.42; 3 studies, 527 participants). </p> <p>There was no difference at other time points.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL: mean change in quality of life measured with CFQ‐R</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in CFQ‐R total score was 0.1 (7.5) points.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in the azithromycin group was 1.6 points higher (0.61 lower to 3.81 higher).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>177</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few differences were found at other time points or with other measurement scales.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ‐R:</b> Cystic Fibrosis Questionnaire ‐ Revised; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>HR:</b> hazard ratio; <b>IV:</b> intravenous; <b>MD:</b> mean difference; <b>NA:</b> not applicable; <b>OR:</b> odds ratio; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once for indirectness as the majority of participants were 18 years or younger. Only 1 study included adults and it is unclear whether the results would be applicable to an adult population. </p> <p>b. Downgraded once for imprecision as most studies reported adverse events, but they were not reported in the same way and we could only include 4 in our meta‐analysis which limited our sample size; there was heterogeneity within the results. </p> <p>c. Downgraded once for imprecision due to a small number of participants from a single trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings ‐ oral azithromycin compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002203-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ high‐dose azithromycin compared to low‐dose azithromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>High‐dose azithromycin versus low‐dose azithromycin for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> high‐dose azithromycin (15 mg/kg/day) </p> <p><b>Comparison:</b> low‐dose azithromycin (5 mg/kg/day) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of</b> </p> <p><b>the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Low‐dose azithromycin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>High‐dose Azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted:</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference in FEV<sub>1</sub> % predicted between baseline and 6 months in either group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results were given as change from baseline within groups and we could not enter the data into our analyses. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: rate of exacerbations per child per month</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) rate of pulmonary exacerbations was 0.10 (0.30) per child/month in the low‐dose group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) rate of pulmonary exacerbations was 0.05 per child/month lower in the high‐dose group (0.20 lower to 0.10 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of children positive for PA over the course of the study was similar between groups, but no information was given on new acquisition. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>NA:</b> not applicable; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to risk of bias within the single included trial; particularly across the domains of allocation concealment, blinding and completeness of data. </p> <p>b. Downgraded once for imprecision due to low participant numbers from a single trial.</p> <p>c. Downgraded once for indirectness as the trial only included children. The results did not translate to an adult population. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ high‐dose azithromycin compared to low‐dose azithromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002203-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ nebulised azithromycin compared to oral azithromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nebulised azithromycin versus oral azithromycin for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> nebulised azithromycin (70 mg once a day via jet nebuliser) </p> <p><b>Comparison:</b> oral azithromycin (500 mg in participants over 40 kg and 250 mg for those below 40 kg 3 times a week) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty</b> </p> <p><b>of the</b> </p> <p><b>evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Oral azithromycin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nebulised azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted: mean change from baseline</b> </p> <p><b>Follow‐up: 28 days</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in FEV<sub>1</sub> % predicted was 5.89% greater in the nebulised azithromycin group compared to the oral group (P &lt; 0.001). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results taken directly from the paper</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: time</b> </p> <p><b>to next exacerbation</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events:</b> number of </p> <p><b>treatment‐related</b> </p> <p><b>adverse events</b> </p> <p><b>Follow‐up: 28 days</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Productive cough was reported more frequently in the nebulised azithromycin group whilst diarrhoea, abdominal cramp, and heartburn were reported more frequently in the oral azithromycin group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported narratively from the paper.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA (</b>mean change in PA count (log<sub>10</sub> PA CFU/g sputum)) </p> <p><b>Follow‐up:</b> 28 days </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a greater decline in PA count in the nebulised azithromycin group. Treatment difference was ‐0.5 log<sub>10</sub> PA CFU/g sputum, P &lt; 0.001. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported directly from the paper.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL: change in PEDsQL‐4 scale</b> </p> <p><b>Follow‐up:</b> 28 days </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was a greater mean change in PEDsQL‐4 scores in the nebulised azithromycin group compared to the oral azithromycin group, treatment effect ‐5.00, P &lt; 0.001. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>a,b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A higher score indicates better QoL.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFU:</b> colony forming units; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>NA:</b> not applicable; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>PEDsQL:</b> Pediatric Quality of Life Inventory; <b>QoL:</b> quality of life. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once due to risk of bias within the single included trial; particularly across the domains of randomisation, allocation concealment, blinding and completeness of data </p> <p>b. Downgraded once for imprecision due to low participant numbers from a single trial</p> <p>c. Downgraded once for indirectness as the trial only included children. The results did not translate to an adult population. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings ‐ nebulised azithromycin compared to oral azithromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002203-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings ‐ weekly azithromycin compared to daily azithromycin</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Weekly versus daily azithromycin for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> weekly azithromycin (1200 mg weekly) </p> <p><b>Comparison:</b> daily azithromycin (250 mg daily) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative</b> </p> <p><b>effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of</b> </p> <p><b>participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty</b> </p> <p><b>of the</b> </p> <p><b>evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Daily azithromycin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Weekly azithromycin</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>FEV<sub>1</sub> % predicted: mean change % predicted</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in FEV<sub>1</sub> was 3.10% predicted (0.80). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in the weekly azithromycin group was 0.70% predicted lower (0.95% lower to 0.45% lower). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Pulmonary exacerbations: number of days to first exacerbation</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) number of days to first exacerbation was 70.00 days (44.80).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of days in the weekly azithromycin group was 17.30 days higher (4.32 higher to 30.28 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events: number of</b> </p> <p><b>treatment‐related</b> </p> <p><b>adverse events</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>233 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>324 per 1000</p> <p>(205 to 469)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.58 (0.85 to 2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal adverse events were more likely in the weekly azithromycin group, OR 3.62 (95% CI 1.61 to 8.14). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Hospitalisations: mean number of hospital admissions</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) number of admissions was 0.60 (1.00).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of admissions in the weekly azithromycin group was the same as the daily group (0.25 lower to 0.25 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>New acquisition of CF pathogens: PA</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study stated only that PA was reported in 66% of participants at baseline and there was no difference between the groups. The percentage did not change over the course of the study. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Need for additional antibiotics</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>QoL: change in CFQ score</b> </p> <p><b>Follow‐up: 6 months</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There was no difference between groups across any domain except for the physical domain, where there was an improvement in the weekly group compared to the daily group of 8.2 points, P = 0.02. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CFQ:</b> Cystic Fibrosis Questionnaire; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub>:</b> forced expiratory volume in one second; <b>NA:</b> not applicable; <b>PA<i>:</i> </b><i>Pseudomonas aeruginosa</i>; <b>QoL:</b> quality of life; <b>SD:</b> standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded once for imprecision due to low participant numbers in a single study</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings ‐ weekly azithromycin compared to daily azithromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/full#CD002203-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002203-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azithromycin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 FEV<sub>1</sub> % predicted (mean change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.99 [1.47, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.33, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐0.12, 5.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 at 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.19 [‐0.31, 10.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [1.74, 6.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.6 at 8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [‐3.25, 12.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.7 at 10 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐7.49, 7.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.8 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐4.96, 4.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 FVC % predicted (percentage change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [‐0.42, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.42 [1.79, 9.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [‐0.35, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 at 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [‐5.37, 10.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.57 [1.71, 7.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [‐2.88, 8.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number free of pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.66 [1.86, 17.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.36, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [1.49, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.38, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.77 [2.26, 51.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Time to first pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.50, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse effects of antibiotic treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Any adverse events occuring during the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Respiratory, thoracic and mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.31, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.99, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.81, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 Wheezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.07, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.7 Productive cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.17, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.8 Sore throat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.9 Increased sputum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.10 Rhinorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.59, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.11 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.12 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.61, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.13 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 16.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.14 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.15 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.39, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.16 Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.57, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.17 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.72, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.18 Hemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.33, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.19 Dizziness (except vertigo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.78, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.20 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.21 Decreased lung function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.51, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.22 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.43, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.23 Hearing impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.07, 18.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.24 Tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.07, 18.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.25 Pulmonary congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.53, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.26 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Overall serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.25, 5.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 DIOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.12, 75.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Admission to hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.17, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.36, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 At 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.51, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Number of days in hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.30 [‐10.63, ‐1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Acquisition of <i>Pseudomonas aeruginosa</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.28, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.21, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.18, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Acquisition of <i>Staphylococcal aureus</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.23, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 after 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.14, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 after 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.28, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.5 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.14, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Eradication of <i>Staphylococcal aureus</i> present at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [0.92, 4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.70, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.90 [0.60, 237.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Acquisition of macrolide‐resistant <i>Staphylococcal aureus</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Acquisition of meticillin‐resistant <i>Staphylococcus aureus</i> (MRSA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.56, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.57, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.20, 5.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 At 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.31, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.01, 6.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Acquisition of <i>Haemophilus influenzae</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.57, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.31, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.28, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 At 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.52, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.4 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Acquisition of macrolide‐resistant <i>Haemophilus influenzae</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Acquisition of non‐tuberculous mycobacterium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.06, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 At 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.04, 11.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Need for additional oral antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 After 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.18, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.19, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 After 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.40, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Number of courses of oral antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Number of days of additional oral antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Need for intravenous antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.60, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 After 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.22, 8.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 After 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.53, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Number of courses of intravenous antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 After 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Number of days of intravenous antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Development of allergic bronchopulmonary aspergillosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.23.1 after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Change in BMI z score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.24.1 at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Mean BMI score at 3 years of age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.09, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Change in weight (kg) from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.25, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.1 After 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.29, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.2 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.26, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.26.3 After 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.02, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Change in total quality of life score (CFQ‐R) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.27.1 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Change in physical domain of CFQ‐R QoL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [0.26, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.1 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.40 [‐8.25, 25.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.28.2 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.09, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Change in respiratory symptom domain of CFQ‐R QoL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Change in psychosocial domain of CFQ‐R QoL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐3.14, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.1 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐12.74, 7.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.2 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐3.00, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Change in body image domain of CFQ‐R QoL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [‐0.54, 6.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.1 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐12.54, 8.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.31.2 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [‐0.24, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Change in eating disorder domain of CFQ‐R QoL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.32.1 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Change in problems with body weight domain of the CFQ‐R QoL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.33.1 at 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Change in inflammatory markers: IL‐8 pg/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.88, ‐0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.34.1 after 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.88, ‐0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Change in inflammatory markers: neutrophil elastase µg/mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.1 after 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.19, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.36 Change in CRP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.36.1 After 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azithromycin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002203-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High dose azithromycin compared to low dose azithromycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Pulmonary exacerbation rate (per child, per month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.20, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.20, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Weight (kg) absolute values <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [‐7.12, 9.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐10.75, 6.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High dose azithromycin compared to low dose azithromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002203-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Weekly versus daily azithromycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Relative change in FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.60, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.40, ‐1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐0.95, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Days to first pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Gastrointestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Abnormal liver transaminases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Study withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Days in hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 after 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Number of hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Acquisition of azithromycin‐resistant <i>Staphylococcal aureus</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 After 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Change in CRP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Weekly versus daily azithromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002203.pub5/references#CD002203-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002203.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002203-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002203-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002203-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002203-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD002203-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002203-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD002203-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002203-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002203-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002203-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002203\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002203\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002203\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002203\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002203\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002203.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002203.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002203.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002203.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002203.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728148950"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002203.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728148954"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002203.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebd6b9893f498',t:'MTc0MDcyODE0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 